oxonic acid has been researched along with Peritoneal Carcinomatosis in 215 studies
Oxonic Acid: Antagonist of urate oxidase.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to determine the feasibility of S-1 plus oxaliplatin (SOX) or capecitabine plus oxaliplatin (XELOX) as first-line therapy for patients with initially unresectable metastases from colorectal cancer." | 7.79 | Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer. ( Akiba, T; Enomoto, H; Kawahara, H; Toyama, Y; Watanabe, K; Yanaga, K, 2013) |
| " Here, we report the case of a patient with systemic sclerosis who developed severe digital ischemia during combination gemcitabine/S-1 chemotherapy for pancreatic cancer." | 7.77 | A case of progressive digital ischemia after early withdrawal of gemcitabine and S-1 in a patient with systemic sclerosis. ( Chiba, T; Ishikawa, S; Kanai, M; Kawaguchi, Y; Masui, T; Matsumoto, S; Mimori, T; Mori, Y; Nishimura, T; Yanagihara, K; Zaima, C, 2011) |
| "We report a patient with type 3 gastric cancer with peritoneal dissemination and hydronephrosis who was successfully treated with intraperitoneal infusion of paclitaxel and oral administration of S-1." | 7.74 | Intraperitoneal administration of paclitaxel and oral S-1 for a patient with peritoneal dissemination and hydronephrosis due to advanced gastric cancer. ( Miki, H; Nakahira, S; Nakata, K; Okada, K; Okamura, S; Sugimoto, K; Takatsuka, Y; Takiuchi, D; Tamura, S; Tomita, N, 2007) |
| "Paclitaxel was used as the first-line drug for treatment of a case with peritoneal recurrence of gastric cancer, accompanied by cancerous ascites." | 7.73 | [A case of paclitaxel-resistant cancerous ascites secondary to gastric carcinoma responding well to TS-1 therapy]. ( Hara, A; Iwamoto, S; Izumi, N; Tsunemi, S; Yamamoto, M, 2006) |
| "Paclitaxel (PTX) was administered via an IP access port implanted in the subcutaneous space." | 5.42 | Cell-free and concentrated ascites reinfusion therapy (CART) for management of massive malignant ascites in gastric cancer patients with peritoneal metastasis treated with intravenous and intraperitoneal paclitaxel with oral S-1. ( Emoto, S; Hanafusa, N; Ishigami, H; Ito, T; Kitayama, J; Watanabe, T; Yamaguchi, H, 2015) |
| "Peritoneal metastasis of gastric cancer has extremely poor clinical outcomes." | 5.40 | Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites. ( Emoto, S; Ishigami, H; Kaisaki, S; Kitayama, J; Watanabe, T; Yamaguchi, H; Yamashita, H, 2014) |
| "We report two cases of advanced gastric cancer." | 5.38 | [Two cases of advanced gastric cancer with peritonitis carcinomatosa that showed disappearance of ascites and obtained a good quality of life by using DIF and paclitaxel]. ( Kodama, M; Mekata, E; Okumura, K; Shiogai, Y; Tan, T; Tani, S, 2012) |
| " Weekly intravenous and intraperitoneal PTX combined with S-1 was highly effective in gastric cancer with malignant ascites." | 5.36 | Weekly intravenous and intraperitoneal paclitaxel combined with S-1 for malignant ascites due to advanced gastric cancer. ( Hidemura, A; Ishigami, H; Kaisaki, S; Kamei, T; Kato, M; Kitayama, J; Miyato, H; Nagawa, H; Otani, K; Soma, D; Yamashita, H, 2010) |
| "After the 5th course, the stenosis of colon and ascites had disappeared in a barium enema and CT scan, respectively." | 5.32 | [A case of advanced type 4 gastric cancer with peritonitis dissemination, navel metastasis effectively treated with combined chemotherapy of biweekly paclitaxel (TXL) and TS-1]. ( Aikou, T; Arima, H; Hamada, N; Hokita, S; Ishigami, S; Maeda, S; Miyazono, F; Natsugoe, S; Takao, S; Takatori, H, 2003) |
| "The aim of this study was to determine the feasibility of S-1 plus oxaliplatin (SOX) or capecitabine plus oxaliplatin (XELOX) as first-line therapy for patients with initially unresectable metastases from colorectal cancer." | 3.79 | Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer. ( Akiba, T; Enomoto, H; Kawahara, H; Toyama, Y; Watanabe, K; Yanaga, K, 2013) |
| "A total of 123 patients with unresectable or recurrent gastric adenocarcinoma with peritoneal metastasis receiving intravenous and intraperitoneal paclitaxel combined with S-1 were retrospectively studied." | 3.78 | Role of intervention for biliary and gastric/intestinal obstruction in gastric cancer with peritoneal metastasis. ( Emoto, S; Hirano, K; Isayama, H; Ishigami, H; Kawakubo, K; Kitayama, J; Kogure, H; Koike, K; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Yamaguchi, H; Yamamoto, N, 2012) |
| " Here, we report the case of a patient with systemic sclerosis who developed severe digital ischemia during combination gemcitabine/S-1 chemotherapy for pancreatic cancer." | 3.77 | A case of progressive digital ischemia after early withdrawal of gemcitabine and S-1 in a patient with systemic sclerosis. ( Chiba, T; Ishikawa, S; Kanai, M; Kawaguchi, Y; Masui, T; Matsumoto, S; Mimori, T; Mori, Y; Nishimura, T; Yanagihara, K; Zaima, C, 2011) |
| "We report a patient with type 3 gastric cancer with peritoneal dissemination and hydronephrosis who was successfully treated with intraperitoneal infusion of paclitaxel and oral administration of S-1." | 3.74 | Intraperitoneal administration of paclitaxel and oral S-1 for a patient with peritoneal dissemination and hydronephrosis due to advanced gastric cancer. ( Miki, H; Nakahira, S; Nakata, K; Okada, K; Okamura, S; Sugimoto, K; Takatsuka, Y; Takiuchi, D; Tamura, S; Tomita, N, 2007) |
| "Paclitaxel was used as the first-line drug for treatment of a case with peritoneal recurrence of gastric cancer, accompanied by cancerous ascites." | 3.73 | [A case of paclitaxel-resistant cancerous ascites secondary to gastric carcinoma responding well to TS-1 therapy]. ( Hara, A; Iwamoto, S; Izumi, N; Tsunemi, S; Yamamoto, M, 2006) |
| " The mean values of 5-fluorouracil (5-FU) concentrations in ascites of the S-1 group at 1-4 h were 414-580 ng/ml (n=5), and those of FT group were 70-87 ng/ml (n=5), with significant differences between the two groups at each observation time." | 3.72 | Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 may be effective against peritoneal dissemination in gastric cancer. ( Hirakawa, K; Nakata, B; Yamagata, S, 2004) |
| "The prognosis of stage III gastric cancer (GC) is not satisfying and the specific chemotherapy regimens for GC of stage IIIC based on the 8th edition of the UICC/AJCC TNM staging system are still inconclusive." | 3.11 | Addition of sintilimab to nanoparticle albumin-bound paclitaxel and S-1 as adjuvant therapy in stage IIIC gastric cancer. ( Feng, T; Li, C; Mei, Y; Shi, M; Yan, C; Yan, M; Yuan, H; Zhang, J; Zhu, Z, 2022) |
| "Six patients with gastric cancer with peritoneal metastasis were enrolled." | 3.01 | Phase 1 Study of Combined Chemotherapy of Nab-Paclitaxel, S-1, and Oxaliplatin for Gastric Cancer with Peritoneal Metastasis (NSOX Study). ( Hayata, K; Katsuda, M; Kitadani, J; Nakamori, M; Nakamura, M; Ojima, T; Yamaue, H, 2021) |
| " Recently, superiority of IP administration of paclitaxel (PTX) combined with S-1 and intravenous PTX over conventional systemic chemotherapy was suggested in a phase III study, although the difference in overall survival did not reach statistical significance in the primary analysis." | 2.94 | Phase I Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Cisplatin for Gastric Cancer with Peritoneal Metastasis. ( Ishigami, H; Kanda, M; Kitayama, J; Kobayashi, D; Kodera, Y; Tanaka, C; Yamaguchi, H, 2020) |
| "Gemcitabine was administered at a dose of 1000 mg/m2 by 30 min infusion on days 1, S-1 40 mg/m2 orally twice daily and LV 25 mg orally twice daily on days 1 to 7 every 2 weeks." | 2.90 | A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer. ( Hakuta, R; Hamada, T; Ijichi, H; Isayama, H; Ishigaki, K; Kishikawa, T; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Saito, K; Saito, T; Sasaki, T; Tada, M; Takahara, N; Takeda, T; Tateishi, K; Uchino, R; Yamamoto, N, 2019) |
| " Major grade 3/4 adverse events during NAC were neutropenia (29." | 2.90 | Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG0501). ( Boku, N; Hirao, M; Ito, Y; Iwasaki, Y; Kaji, M; Katai, H; Katayama, H; Kimura, Y; Kurita, A; Mizusawa, J; Nakamura, K; Sano, T; Sasako, M; Takagi, M; Terashima, M; Yamada, M; Yoshikawa, T, 2019) |
| "Patients diagnosed with CY+ advanced gastric cancer and treated with S-1-based therapy were enrolled." | 2.84 | Retrospective comparison of S-1 plus cisplatin versus S-1 monotherapy for the treatment of advanced gastric cancer patients with positive peritoneal cytology but without gross peritoneal metastasis. ( Chin, K; Hiroki, O; Ichimura, T; Matsushima, T; Nakayama, I; Ogura, M; Ozaka, M; Shinozaki, E; Suenaga, M; Takahari, D; Wakatsuki, T; Yamaguchi, K, 2017) |
| "Paclitaxel was administered i." | 2.84 | Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis. ( Fujii, T; Honda, G; Isayama, H; Ishigami, H; Kodera, Y; Kon, M; Kurata, M; Mizuma, M; Motoi, F; Satoi, S; Takahara, N; Unno, M; Yamada, S; Yamamoto, T; Yanagimoto, H, 2017) |
| " Grade 3 or worse adverse events were less frequent in the elderly group receiving SOX than in the elderly group receiving CS except for the low incidence of sensory neuropathy (5." | 2.82 | Efficacy and safety of S-1 and oxaliplatin combination therapy in elderly patients with advanced gastric cancer. ( Amagai, K; Bando, H; Chin, K; Fujii, H; Gotoh, M; Hamada, C; Hironaka, S; Hyodo, I; Imamura, H; Miwa, H; Nishikawa, K; Nishina, T; Niwa, Y; Shimada, K; Sugimoto, N; Tanabe, S; Tsuda, M; Tsuji, A; Yamada, Y; Yamaguchi, K; Yasui, H, 2016) |
| "Postoperative complications were identified in 18 patients and the overall morbidity rate was 26." | 2.79 | Low creatinine clearance is a risk factor for D2 gastrectomy after neoadjuvant chemotherapy. ( Aoyama, T; Cho, H; Hayashi, T; Ito, Y; Miyashita, Y; Morita, S; Nishikawa, K; Ogata, T; Sakamoto, J; Tanabe, K; Tsuburaya, A; Yoshikawa, T, 2014) |
| " This phase 2 study evaluated the benefits and tolerability of weekly intravenous and intraperitoneal paclitaxel (PTX) treatment combined with oral S-1 in patients with gastric cancer who had macroscopic peritoneal metastasis." | 2.78 | A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis. ( Emoto, S; Ishigami, H; Kitayama, J; Watanabe, T; Yamaguchi, H; Yamashita, H, 2013) |
| "Peritoneal metastasis is treated more effectively by this regimen than other forms of metastases." | 2.78 | Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor. ( Chen, Y; Cui, Y; Feng, Y; Li, Q; Liu, T; Wang, Y; Yu, Y, 2013) |
| "S-1 in patients with advanced gastric cancer (AGC)." | 2.78 | Randomized phase II study comparing paclitaxel with S-1 vs. S-1 as first-line treatment in patients with advanced gastric cancer. ( Lu, XY; Wang, ML; Wang, X; Yang, JF; Yu, HG; Zhou, LY, 2013) |
| "The standard of care for gastric cancer with peritoneal metastasis is chemotherapy." | 2.77 | [The updated treatment strategy for gastric cancer with peritoneal metastasis]. ( Ishigami, H; Kaisaki, S; Kitayama, J, 2012) |
| "Paclitaxel was administered intraperitoneally at 80 mg/m(2)." | 2.77 | A preliminary study of single intraperitoneal administration of paclitaxel followed by sequential systemic chemotherapy with S-1 plus paclitaxel for advanced gastric cancer with peritoneal metastasis. ( Furukawa, H; Imamoto, H; Imano, M; Inoue, K; Itoh, T; Kato, H; Nishida, S; Nishikawa, M; Okuno, K; Peng, YF; Satou, T; Shinkai, M; Shiozaki, H; Takeyama, Y; Tsubaki, M; Yasuda, A; Yasuda, T, 2012) |
| "Eighteen patients with advanced gastric cancer in addition to confirmed peritoneal metastasis using laparoscopy were enrolled in this study." | 2.76 | Intraperitoneal infusion of paclitaxel with S-1 for peritoneal metastasis of advanced gastric cancer: phase I study. ( Higashijima, J; Iwata, T; Kurita, N; Miyatani, T; Morimoto, S; Nakao, T; Nishioka, M; Shimada, M; Yoshikawa, K, 2011) |
| " paclitaxel (PTX) combined with S-1 was carried out in gastric cancer patients with peritoneal metastasis." | 2.75 | Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. ( Hidemura, A; Ishigami, H; Kaisaki, S; Kamei, T; Kato, M; Kitayama, J; Miyato, H; Nagawa, H; Otani, K; Soma, D; Yamashita, H, 2010) |
| "CEA mRNA (+) patients with gastric cancer were treated postoperatively with S-1 monotherapy." | 2.75 | Phase II clinical trial of postoperative S-1 monotherapy for gastric cancer patients with free intraperitoneal cancer cells detected by real-time RT-PCR. ( Ito, S; Kodera, Y; Kojima, T; Mochizuki, Y; Nakanishi, H; Yamamura, Y, 2010) |
| "Twelve gastric cancer patients with positive cytology were enrolled in this study." | 2.75 | Feasibility study of S-1 and intraperitoneal docetaxel combination chemotherapy for gastric cancer with peritoneal dissemination. ( Doki, Y; Fujiwara, Y; Miyata, H; Moon, JH; Mori, M; Nakajima, K; Nishida, T; Takiguchi, S; Yamamoto, K; Yamasaki, M, 2010) |
| "Patients with advanced gastric cancer, naive to chemotherapy or not refractory to fluoropyrimidine, were enrolled." | 2.75 | Phase I study of docetaxel, cisplatin and S-1 in patients with advanced gastric cancer. ( Boku, N; Hironaka, S; Kojima, T; Machida, N; Muro, K; Shitara, K; Taku, K; Ueda, S; Yamazaki, K; Yokota, T, 2010) |
| " A pharmacokinetic study of PTX was also performed." | 2.74 | Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer. ( Hidemura, A; Ishigami, H; Kaisaki, S; Kamei, T; Kitayama, J; Miyato, H; Nagawa, H; Otani, K; Soma, D; Yamashita, H, 2009) |
| "The prognosis of advanced gastric cancer patients complicated with positive lavage cytology is poor, similar with that of peritoneal dissemination." | 2.73 | [Treatment for advanced gastric cancer with positive lavage cytology-systemic versus intraperitoneal chemotherapy]. ( Iwagami, S; Iwanaga, T; Iwasaki, Y; Matsumoto, H; Nakano, D; Nunobe, S; Ohashi, M; Takahashi, K; Yamaguchi, T, 2008) |
| "An early detection and treatment of gastric cancer with peritoneal dissemination are rather difficult so that a clinical trial has been neglected." | 2.73 | [Neoadjuvant chemotherapy for gastric cancer with peritoneal dissemination]. ( Doki, Y; Fujiwara, Y; Miyata, H; Monden, M; Nishida, T; Takiguchi, S; Yamazaki, M, 2007) |
| "To determine the safety profile and activity of IP docetaxel combined with S-1 for patients with peritoneal dissemination of gastric cancer, a multi-centric phase I/II study has started." | 2.73 | [A multi-centric phase I/II study of intraperitoneal docetaxel combined with S-1 for patients with peritoneal dissemination of gastric cancer]. ( Fujimura, T; Fukushima, N; Fushida, S; Goda, F; Hirono, Y; Imano, M; Kaji, M; Kurita, A; Kurita, N; Nashimoto, A; Ohta, T; Tanemura, H; Tsujitani, S; Watanabe, Y; Yamaguchi, K, 2007) |
| "We treated 12 patients with advanced gastric cancer with 80 mg/m2 of S-1 for 21 days and 60 mg/m2 of cisplatin (CDDP) on day 8 every 5 weeks." | 2.71 | Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer. ( Baba, H; Endo, K; Ikeda, Y; Kohnoe, S; Okamura, T; Toh, Y; Yamamoto, M, 2003) |
| "S-1 showed promising activity against gastric cancer with peritoneal dissemination and acceptable toxicity." | 2.71 | Pilot study of S-1 in patients with disseminated gastric cancer. ( Hayashi, K; Kitamura, Y; Oguma, H; Sasagawa, T; Takasaki, K, 2003) |
| "TS-1 is a promising drug for gastric cancer with peritoneal dissemination." | 2.70 | [The clinical effect of TS-1 in advanced and recurrent gastric cancer with peritoneal dissemination]. ( Chiba, M; Hayashi, K; Inaba, Y; Kamio, Y; Koyama, M; Ohe, S; Watabe, S, 2002) |
| "Nearly 70% of gastric cancer recurrences occur as peritoneal dissemination." | 2.55 | [A Case of QOL Improvement after Intestinal Stenosis Due to Peritoneal Dissemination of Gastric Cancer in Elderly Patients]. ( Furuke, Y; Ikeda, J; Imura, K; Komatsu, S; Kumano, T; Nakatsugawa, Y; Shimomura, K; Shioaki, Y; Tanaka, Y; Taniguchi, F, 2017) |
| "Advanced gastric cancers have a poor course in terms of the development of peritoneal carcinomatosis and prognosis, even if the curative resection has been performed." | 2.55 | The Importance of Extensive Intraoperative Peritoneal Lavage as a Promising Method in Patients with Gastric Cancer Showing Positive Peritoneal Cytology Without Overt Peritoneal Metastasis and Other Therapeutic Approaches. ( Alemdar, A; Bas, K; Ilhan, E; Ureyen, O, 2017) |
| "A 64-year-old man with type 3 advanced gastric cancer was referred to our hospital." | 2.52 | [A case of highly advanced gastric cancer with peritoneal dissemination -- a histological CR to S-1 and CDDP combination chemotherapy]. ( Ito, S; Ito, Y; Kurahashi, S; Misawa, K; Niwa, Y; Shimizu, Y; Yatabe, Y, 2015) |
| "An 80-year-old man with type 4 gastric cancer in the mid-gastric region underwent total gastrectomy and D2-No." | 2.52 | [Long-Term Disease-Free Survival through Postoperative Chemotherapy in a Case of Gastric Cancer with Peritoneal Dissemination]. ( Ito, M; Kitano, M; Kunishige, T; Matsumoto, S; Migita, K; Nakade, H; Nakajima, Y; Nakatani, M; Tanaka, T; Wakatsuki, K, 2015) |
| "The patient was a 71-year-old man with gastric cancer of Borrmann type 3 accompanied with N3." | 2.49 | [Curative resection of a case of advanced gastric cancer with peritoneal dissemination responding well to combination chemotherapy of docetaxel,cisplatin and S-1]. ( Atsumi, Y; Hasegawa, S; Imada, T; Masuda, M; Nemoto, H; Oshima, T; Rino, Y; Sato, T; Tamagawa, H; Uchiyama, M; Yoshikawa, T; Yukawa, N, 2013) |
| "Hence, he was diagnosed with advanced jejunal cancer with distant metastasis (T4N1M0 stage)." | 2.49 | [A case of jejnal cancer who was controlled peritoneal metastasis, successfully by combination therapy with docetaxel and S-1]. ( Fujita, H; Fujita, J; Funaki, H; Kaida, D; Kinami, S; Kosaka, T; Morioka, E; Nakano, Y; Noguchi, M; Ohnishi, T; Ohno, Y; Tomita, Y; Ueda, N, 2013) |
| "Without any sign of infection, leukocytosis developed around the 30th POD." | 2.46 | Aggressive recurrence of gastric cancer as a granulocyte-colony-stimulating factor-producing tumor. ( Asada, Y; Fujisawa, K; Iida, Y; Kawaguchi, M; Mitsui, T; Miura, S; Munemoto, Y; Sudo, Y; Takehara, A; Terada, T, 2010) |
| "We aimed to evaluate pancreatic cancer (PC) with positive peritoneal lavage cytology (CY1) outcomes following a change in adjuvant therapy." | 1.72 | Postoperative Treatment of Resectable Pancreatic Cancer With Positive Peritoneal Lavage Cytology: A Multicentre Retrospective Study. ( Asagi, A; Furuse, J; Higuchi, R; Konishi, M; Mizuno, N; Morinaga, S; Motoi, F; Nagano, H; Nara, S; Okuyama, H; Shioji, K; Shirakawa, H; Sugimachi, K; Todaka, A; Toshiyama, R; Tsumura, H, 2022) |
| "This was a real-world study of gastric cancer patients with peritoneal metastasis who have been treated with AS or SOX regimen as first-line chemotherapy." | 1.72 | Efficacy of AS versus SOX regimen as first-line chemotherapy for gastric cancer patients with peritoneal metastasis: a real-world study. ( Cui, Y; Li, Q; Li, W; Liu, T; Wang, Y; Yu, S; Yu, Y; Zhang, J; Zhang, L, 2022) |
| "We report a case of advanced gastric cancer with peritoneal metastasis achieved pathological complete response by chemotherapy." | 1.56 | [A Case of Advanced Gastric Cancer with Peritoneal Metastasis Achieved Pathological Complete Response by Chemotherapy(SOX Regimen)]. ( Danno, K; Ikeda, K; Kawagishi, S; Nishigaki, T; Oka, Y; Sugimoto, K; Takahashi, K; Takeyama, H; Taniguchi, H; Tokunaga, T; Toyoda, Y; Yamamoto, H; Yamashita, M, 2020) |
| " She underwent chemotherapy comprisingintravenous and intraperitoneal paclitaxel combined with S-1." | 1.51 | [A Case of Robot-Assisted Conversion Surgery for Gastric Cancer with Peritoneal Dissemination That Responded to Intravenous and Intraperitoneal Paclitaxel Combined with S-1 Chemotherapy]. ( Amano, S; Goto, A; Hanai, T; Hattori, Y; Inaba, K; Kadoya, S; Kato, Y; Kikuchi, K; Nakamura, K; Nakauchi, M; Sugioka, A; Tomatsu, M; Tsuru, Y; Uyama, I, 2019) |
| "A scirrhous gastric cancer was found, and he was introduced to us." | 1.51 | [Multi-Look Staging Laparoscopy and Conversion Surgery for Gastric Cancer with Peritoneal Metastases]. ( Doki, Y; Kurokawa, Y; Makino, T; Miyazaki, Y; Mori, M; Nakajima, K; Noma, T; Takahashi, T; Tanaka, K; Yamasaki, M, 2019) |
| "Patients with advanced gastric cancer and severe peritoneal metastasis were included if they had massive ascites and/or inadequate oral intake requiring intravenous nutritional support." | 1.51 | Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study. ( Arai, H; Boku, N; Fukuda, N; Hironaka, S; Iwasa, S; Kawahira, M; Masuishi, T; Minashi, K; Muro, K; Nakajima, TE; Takahari, D; Yasui, H, 2019) |
| "A 27-year-old woman was diagnosed with gastric cancer complicated peritoneal dissemination and direct invasion to pancreas via staging laparoscopy." | 1.48 | [Advanced Gastric Cancer with Peritoneal Dissemination Treated with Conversion Surgery after S-1 and CDDP Chemotherapy - A Case Report]. ( Hasegawa, H; Kakeji, Y; Kanaji, S; Matsuda, T; Matsuda, Y; Nakamura, T; Oshikiri, T; Sumi, Y; Suzuki, S; Ueta, K; Yamamoto, M; Yamashita, K, 2018) |
| "In the latest Japanese gastric cancer treatment guidelines, PAM plus paclitaxel(PTX)was positioned as a second-line chemotherapy for advanced gastric cancer." | 1.48 | [A Case of Advanced Gastric Cancer with Peritoneal Dissemination after Gastrectomy Effectively Treated with Combination Chemotherapy of Ramucirumab and Paclitaxel]. ( Akaishi, T; Hakamada, K; Hara, Y; Kubo, N; Mitsuhashi, Y; Muroya, T; Ogasawara, H; Sato, K; Umemura, K; Umetsu, S; Wajima, N; Wakasa, Y; Yoshida, E; Yoshida, T, 2018) |
| "A 58-year-old man was diagnosed with gastric cancer in 2006." | 1.48 | [A Case of Peritoneal Dissemination of Metastatic Gastric Cancer with Successful Docetaxel and S-1 Combination Therapy]. ( Fujiwara, A; Hama, N; Hamakawa, T; Hirao, M; Kato, S; Kato, T; Maeda, S; Miyake, M; Miyamoto, A; Miyazaki, M; Nakamori, S; Nishikawa, K; Sekimoto, M; Takami, K; Uemura, M, 2018) |
| "The outcome of gastric cancer patients with peritoneal metastasis remains poor." | 1.46 | Peritoneal Lavage CEA mRNA Levels Predict Conversion Gastrectomy Outcomes after Induction Chemotherapy with Intraperitoneal Paclitaxel in Gastric Cancer Patients with Peritoneal Metastasis. ( Ishigami, H; Kitayama, J; Kurihara, M; Satoh, Y; Yamaguchi, H; Yatomi, Y, 2017) |
| "We report herein a rare case of gastric cancer with peritoneal dissemination who achieved 5- year survival after surgery along with the literature review." | 1.43 | [A Patient with Gastric Cancer with Peritoneal Dissemination Who Survived for Five Years after Sequential Chemotherapy with S-1 Followed by Paclitaxel]. ( Kakiuchi, Y; Takashima, H; Urano, S, 2016) |
| "Advanced sigmoid colon cancer with stenosis was discovered in a man in his 50's who presented with constipation." | 1.43 | [Pathological Complete Response to SOX plus Bevacizumab for Treating Stage IV Sigmoid Colon Cancer]. ( Emi, M; Hirabayashi, N; Ibuki, Y; Kagimoto, A; Kaneko, M; Mukaida, H; Takiyama, W; Yoshimitsu, M, 2016) |
| "Paclitaxel (PTX) was administered via an IP access port implanted in the subcutaneous space." | 1.42 | Cell-free and concentrated ascites reinfusion therapy (CART) for management of massive malignant ascites in gastric cancer patients with peritoneal metastasis treated with intravenous and intraperitoneal paclitaxel with oral S-1. ( Emoto, S; Hanafusa, N; Ishigami, H; Ito, T; Kitayama, J; Watanabe, T; Yamaguchi, H, 2015) |
| "Among 790 gastric cancer patients between 2005 and 2009, 52 cases of CY1 were identified (6." | 1.42 | Reduced preoperative serum albumin and absence of peritoneal dissemination may be predictive factors for long-term survival with advanced gastric cancer with positive cytology test. ( Hoshi, K; Hosoda, K; Katada, N; Kikuchi, S; Mieno, H; Moriya, H; Ushiku, H; Watanabe, M; Yamashita, K, 2015) |
| "The standard treatment of gastric cancer patients with PD is combination therapy with S-1 and cisplatin (SP therapy)." | 1.42 | [S-1 plus Cisplatin Combination Therapy for Gastric Cancer with Peritoneal Dissemination]. ( Akita, H; Fujiwara, Y; Gotoh, K; Hara, T; Kobayashi, S; Miyoshi, N; Motoori, M; Noura, S; Ohue, M; Omori, T; Sakon, M; Sugimura, K; Takahashi, H; Yano, M, 2015) |
| "Treatment of the endometrial cancer with cytoreductive surgery followed by adjuvant chemotherapy was performed first." | 1.42 | [A Case of Double Cancers of the Stomach and Endometrium with Peritoneal Metastasis]. ( Arimitsu, H; Chibana, T; Ikeda, A; Imanishi, S; Ishige, F; Kainuma, O; Kobayashi, R; Nabeya, Y; Sasaki, K; Souda, H; Takiguchi, N; Tonooka, T; Yamamoto, H, 2015) |
| "Here, we report 2 patients with gastric cancer and peritoneal dissemination who were successfully treated with chemotherapy after undergoing treatment for an oncologic emergency caused by peritoneal dissemination." | 1.42 | [Introduction of Chemotherapy for Advanced Gastric Cancer Showing Oncologic Emergency Caused by Peritoneal Dissemination--Report of Tow Cases]. ( Akita, H; Fujiwara, Y; Gotoh, K; Kobayashi, S; Miyata, H; Miyoshi, N; Noura, S; Ohue, M; Omori, T; Sakon, M; Sugimura, K; Takahashi, H; Yano, M, 2015) |
| "Patients with stage III gastric cancer who underwent D2 gastrectomy were enrolled." | 1.40 | Survival analysis of adjuvant chemotherapy with S-1 plus cisplatin for stage III gastric cancer. ( Fuse, N; Goto, M; Hamaguchi, T; Ito, S; Katai, H; Konishi, M; Sano, T; Sasako, M; Shirao, K; Takahari, D; Tanigawa, N; Terashima, M; Yasui, H; Yoshimura, K, 2014) |
| "Peritoneal metastasis of gastric cancer has extremely poor clinical outcomes." | 1.40 | Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites. ( Emoto, S; Ishigami, H; Kaisaki, S; Kitayama, J; Watanabe, T; Yamaguchi, H; Yamashita, H, 2014) |
| "Management of peritoneal disseminated gastric cancer (GC) remains a challenging problem." | 1.40 | Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan. ( Canbay, E; Hirano, M; Ichinose, M; Ishibashi, H; Mizumoto, A; Sako, S; Takao, N; Yonemura, Y, 2014) |
| "Unresectable metastatic colorectal cancer with very slow tumour growth rate does not necessarily require for strong short-interval chemotherapy." | 1.40 | Usefulness of monthly chemotherapy for patients with unresectable metastatic colorectal cancer. ( Akiba, T; Enomoto, H; Kawahara, H; Tomoda, M; Watanabe, K; Yanaga, K, 2014) |
| "Here we report a case of unresected gastric cancer that maintained long tumor dormancy by use of paclitaxel+S-1 combination therapy." | 1.40 | [A case of unresected gastric cancer that maintained long tumor dormancy by use of paclitaxel+S-1 combination therapy]. ( Aisu, N; Hoshino, S; Maki, K; Naito, M; Nakagawa, M; Yamashita, Y; Yoshida, Y, 2014) |
| " The goal of this study was to evaluate the efficacy and safety of combination therapy of cetuximab and S-1 combined with oxaliplatin (SOX) in Chinese patients with advanced gastric cancer." | 1.40 | Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer. ( Chen, XB; Hua, YW; Kong, Y; Liu, HX; Ma, EM; Yang, W; Zhang, B; Zhang, YL; Zhang, ZD, 2014) |
| "Gastric adenosquamous carcinoma is a rare malignancy with a poor prognosis." | 1.40 | [A case of gastric adenosquamous carcinoma with peritoneal dissemination in which treatment with S-1 plus paclitaxel therapy resulted in improved long-term survival]. ( Hirano, M; Ichinose, M; Mizumoto, A; Ozamoto, Y; Takao, N; Tatsuno, M; Togawa, T; Yamamoto, Y; Yonemura, Y, 2014) |
| "We report a case of gastric cancer with peritoneal dissemination that was successfully treated with low-dose S-1 or capecitabine chemotherapy over a 5-year period." | 1.40 | [A case of gastric cancer with peritoneal dissemination successfully treated with low-dose S-1 or capecitabine chemotherapy for five years]. ( Hara, Y; Minami, Y; Nakamura, T; Ueda, S, 2014) |
| "We report a case of advanced gastric cancer that was successfully treated with second-line chemotherapy followed by curative conversion gastrectomy." | 1.40 | [A case of advanced gastric cancer successfully treated with second-line chemotherapy followed by curative conversion gastrectomy]. ( Asaoka, T; Endo, S; Fujitani, K; Fukuda, Y; Fukui, A; Fushimi, H; Harada, Y; Haraguchi, N; Hirao, M; Ikeda, M; Iwase, K; Kawada, J; Miyake, M; Miyamoto, A; Miyazaki, M; Nakamori, S; Nishikawa, K; Sekimoto, M; Takagi, M; Yamamoto, K, 2014) |
| "A gastric cancer recurrence with paraaortic lymph node (PALN) metastasis was diagnosed fifteen months after the operation." | 1.40 | [A case of successful treatment of peritoneal dissemination from gastric cancer with S-1/DOC chemotherapy]. ( Ebisui, C; Fukuchi, N; Kinuta, M; Murata, K; Nushijima, Y; Okada, K; Okamura, S; Yanagisawa, T; Yokouchi, H, 2014) |
| "A 35-year-old female with scirrhous stomach cancer (stage IV) was treated with a combination of 5-aminolevulinic acid (ALA), sodium dichloroacetate (DCA), hyperthermotherapy, and immunotherapy as terminal care." | 1.39 | A patient with scirrhous stomach cancer treated with combination of hyperthermotherapy and 5-aminolevulinic acid (ALA). ( Goto, S; Kamigaki, T; Saito, M; Yano, K, 2013) |
| "AFP-producing gastric cancer with peritoneal metastasis has a poor prognosis, but chemotherapy, mainly with S-1 and trastuzumab, was effective for it." | 1.39 | [A case of AFP-producing gastric cancer with peritoneal metastasis treated effectively with chemotherapy, mainly using S-1 and trastuzumab]. ( Ishikawa, H; Ishioka, K; Ko, S; Matsusaka, M; Mukogawa, T; Nishiwada, S; Watanabe, A; Yoshikawa, T, 2013) |
| "Twenty-eight patients with advanced gastric cancer underwent gastrectomy without preoperative chemotherapy." | 1.39 | Adjuvant chemotherapy with S-1 followed by docetaxel for gastric cancer and CY1P0 peritoneal metastasis after relatively curative surgery. ( Fujita, I; Kanazawa, Y; Kato, S; Onodera, H; Uchida, E, 2013) |
| "He survived without recurrence for approximately 2 years after gastrectomy." | 1.39 | [A case of advanced gastric cancer with peritoneal dissemination recurrence after gastrectomy effectively treated with combination chemotherapy of S-1 and docetaxel]. ( Ebisui, C; Fukuchi, N; Kato, R; Kinuta, M; Makino, S; Murata, K; Okada, K; Okamura, S; Takeoka, T; Wada, Y; Yanagisawa, T; Yokouchi, H, 2013) |
| "Rectal stenosis was improved and complete remission was maintained until May 2013." | 1.39 | [A case of rectal stenosis due to peritoneal dissemination from gastric cancer that was treated with chemoradiation therapy]. ( Cho, H; Fujikawa, H; Iwasaki, K; Kasahara, A; Masuda, M; Ogata, T; Osaragi, T; Rino, Y; Shirai, J; Sujishi, K; Tsuburaya, A; Yamada, T; Yamamoto, Y; Yoneyama, K; Yoshikawa, T, 2013) |
| " Two cycles of intraperitoneal chemotherapy with docetaxel combined with S-1, were administrated and gastrectomy with lymph node dissection was performed in cases without macroscopic PC at post-NIPS staging laparoscopy." | 1.38 | Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination. ( Doki, Y; Fujiwara, Y; Kurokawa, Y; Miyata, H; Mori, M; Nakajima, K; Takiguchi, S; Yamasaki, M, 2012) |
| "We report two cases of advanced gastric cancer." | 1.38 | [Two cases of advanced gastric cancer with peritonitis carcinomatosa that showed disappearance of ascites and obtained a good quality of life by using DIF and paclitaxel]. ( Kodama, M; Mekata, E; Okumura, K; Shiogai, Y; Tan, T; Tani, S, 2012) |
| "A 59-year-old man with type 3 gastric cancer(signet-ring cell carcinoma)underwent simple laparotomy because of peritoneal dissemination." | 1.38 | [A long-surviving patient with unresectable advanced gastric cancer treated with S-1 and biweekly paclitaxel combination chemotherapy as second-line treatment]. ( Goto, M; Hirata, Y; Kawahara, Y; Kitamura, M; Nakayama, M; Ohta, R; Oneyama, M; Sekikawa, K; Shimoda, Y; Takahashi, Y, 2012) |
| "We report a gastric cancer patient with positive peritoneal lavage cytology (CY1) who achieved 20-month progression free survival by S-1 monotherapy." | 1.38 | [S-1 monotherapy achieved twenty-month survival for peritoneal lavage cytology-positive gastric cancer patient undergoing noncurative resection]. ( Kiyokawa, T; Nishida, M; Seto, Y; Shimoyama, S, 2012) |
| "Borrmann-type 3 gastric cancer with hemorrhaging was revealed by stomach endoscopy." | 1.37 | [A case of gastric cancer with peritoneal dissemination successfully treated by S-1/paclitaxel combination chemotherapy]. ( Shoji, T, 2011) |
| "Gluteal recurrence of the original gastric cancer was suggested, and systemic chemotherapy consisting of S-1 at 100 mg/day (3 weeks on, 1 week off) and CDDP (day 8) was started." | 1.37 | Good response chemotherapy for late-recurring gastric cancer in the gluteals, with peritoneal and retroperitoneal dissemination. ( Deguchi, R; Iwata, Y; Mine, T; Numata, M; Ogasawara, F; Ohtani, Y; Sakuma, T; Sato, S; Takashimizu, S, 2011) |
| " We judged that curative resection was impossible and finished the operation after giving an intra-abdominal dosage of cisplatin(CDDP)at 85mg." | 1.37 | [A case of gastric carcinoma with peritoneal metastasis successfully treated by combination chemotherapy of S-1 and cisplatin]. ( Gon, H; Ishida, T; Iwasaki, T; Kanemitsu, K; Nakajima, T; Okuda, T; Tanaka, K; Toyokawa, A; Yamashita, H, 2011) |
| "We report two cases of advanced gastric cancer successfully treated with combination S-1 and docetaxel (DOC) therapy." | 1.36 | [Two cases of advanced gastric cancer with peritoneal dissemination, and Virchow's metastases successfully treated by combination therapy of S-1 and docetaxel]. ( Hasegawa, H; Kijima, T; Kitahara, M; Kubo, H; Miyahara, M; Tada, K, 2010) |
| "Paclitaxel 50mg/m2 was administered on days 1 and 8." | 1.36 | [Combination of S-1 and paclitaxel for advanced/recurrent gastric cancer patients with peritoneal metastasis, feasibility study (OGSG0401)]. ( Fujitani, K; Furukawa, H; Kimura, Y; Machida, H; Shimokawa, T; Takiuchi, H; Tominaga, K; Tsujinaka, T; Yamamoto, M; Yano, H, 2010) |
| " Weekly intravenous and intraperitoneal PTX combined with S-1 was highly effective in gastric cancer with malignant ascites." | 1.36 | Weekly intravenous and intraperitoneal paclitaxel combined with S-1 for malignant ascites due to advanced gastric cancer. ( Hidemura, A; Ishigami, H; Kaisaki, S; Kamei, T; Kato, M; Kitayama, J; Miyato, H; Nagawa, H; Otani, K; Soma, D; Yamashita, H, 2010) |
| "In advanced gastric cancer with peritoneal metastasis, adjuvant chemotherapy after primary tumor resection showed considerably poor prognosis with a median survival time of only 232 days." | 1.36 | [Strategy of treatment for gastric cancer with peritoneal metastasis]. ( Adachi, T; Hatoh, T; Matsui, K; Oshita, H; Tanemura, H; Yamada, M, 2010) |
| "Paclitaxel was administered at 120 mg/m(2) on day 1 and S-1 was administered orally at 80 mg/m(2) for 14 consecutive days, followed by a 1-week rest, as one course." | 1.36 | Pilot study of a combination of S-1 and paclitaxel for patients with peritoneal metastasis from gastric cancer. ( Egawa, C; Miki, H; Nakahira, S; Nakata, K; Okada, K; Okamura, S; Sugimoto, K; Suzuki, R; Takatsuka, Y; Takeno, A; Tamura, S; Uji, K; Yoshida, A, 2010) |
| "No re-growth of gastric cancer has been seen for 9 months with this chemotherapy." | 1.36 | [A very elderly case of recurrent gastric cancer with peritoneal dissemination effectively treated by combination chemotherapy of docetaxel (DOC) and S-1]. ( Hachisuka, T; Hattori, K; Kinoshita, T; Miyauchi, M; Mori, T; Shikano, T; Shinohara, M; Yamamoto, T, 2010) |
| "A 75-year-old man with advanced gastric cancer underwent distal gastrectomy with lymph node dissection(D1)and Roux-en Y reconstruction." | 1.35 | [A case of Stage IV gastric cancer with liver and peritoneal metastases responding completely to tailored S-1/CPT- 11 combination therapy]. ( Arai, H; Kashiwabara, M; Maruyama, H; Matsuda, A; Matsushita, A; Matsutani, T; Miyamoto, M; Mizutani, T; Nishi, Y; Sasajima, K; Suzuki, S; Tajiri, T; Yanagi, K; Yokoyama, T, 2008) |
| "They were diagnosed with unresectable gastric cancer with severe peritoneal dissemination by staging laparoscopy, or with metastasis to the transverse colon." | 1.35 | Pilot study of intraperitoneal administration of paclitaxel and oral S-1 for patients with peritoneal metastasis due to advanced gastric cancer. ( Miki, H; Miyake, T; Nakahira, S; Nakata, K; Okada, K; Okamura, S; Sugimoto, K; Suzuki, R; Takatsuka, Y; Tamura, S; Yoshimura, M, 2008) |
| "The patient was diagnosed with typeIII gastric cancer by gastroendoscopy postoperatively." | 1.35 | [A case of perforated gastric cancer in which resection for elimination was possible S-1/CDDP combined chemotherapy for peritonitis carcinomatosa]. ( Itakura, T; Sugimoto, T; Uesaka, K, 2009) |
| "Two unresectable advanced gastric cancer cases with peritoneal metastases were successfully treated by the combination therapy of S-1 and paclitaxel." | 1.35 | [Two advanced gastric cancer cases with peritoneal metastases successfully treated by s-1/paclitaxel combination therapy]. ( Ando, T; Furuta, R; Goto, H; Ina, K; Kataoka, T; Kayukawa, S; Masaki, A; Nagao, S; Nishio, T, 2009) |
| "Abdominal CT scan revealed pancreatic cancer with massive ascites showing peritoneal dissemination, combined with lymph node and liver metastases." | 1.35 | [A resected case of effective treatment with S-1/gemcitabine and Paclitaxel combination chemotherapy for advanced pancreatic cancer with peritoneal and liver metastases]. ( Fushida, S; Kimura, H; Mukawa, A, 2009) |
| "We encountered a patient with gastric cancer demonstrating peritoneal dissemination, who was successfully treated by combination therapy using S-1 and docetaxel." | 1.35 | [A case of gastric cancer with peritoneal dissemination-efficacy of combination therapy with S-1 and docetaxel]. ( Futagawa, S; Kitajima, M; Konishi, N; Marusasa, T; Nishimura, K; Ochiai, T; Satoh, G; Watanabe, T, 2009) |
| "The prognosis of gastric cancer patients with peritoneal dissemination is poor." | 1.35 | Induction chemotherapy with S-1 plus cisplatin followed by surgery for treatment of gastric cancer with peritoneal dissemination. ( Hosogi, H; Obama, K; Okabe, H; Sakai, Y; Ueda, S, 2009) |
| "The subjects were type 4 advanced gastric cancer cases from October 2002 to December 2007 who underwent st-lap, as well as 7 P0 and CY0 [P(-)] cases (the operative group), and 18 P(+) cases which underwent chemotherapy (the chemotherapy group)." | 1.35 | [Outcome of therapy for type 4 gastric cancer with peritoneal metastasis--diagnosis by laparoscopy and effect of chemotherapy]. ( Egawa, C; Miki, H; Nakahira, S; Nakata, K; Okada, K; Okamura, S; Sugimoto, K; Suzuki, R; Takatsuka, Y; Tamura, S; Uji, K; Yoshida, A; Yoshimura, M; Yoshioka, Y, 2009) |
| "Most gastric cancer patients with peritoneal dissemination die within a few months, and there is no standard treatment for peritoneal dissemination from gastric cancer." | 1.35 | [A case of gastric cancer with peritoneal dissemination which has been alive more than three years responding to intraperitoneal chemotherapy]. ( Asami, S; Hirata, M; Idani, H; Kin, H; Kubo, S; Kumano, K; Kurose, Y; Muro, M; Nojima, H; Sasaki, H; Takakura, N; Yamashita, T; Yoshioka, T, 2009) |
| "Gemcitabine (1,000 mg/m2) was intravenously administered 3 times (on days 1, 8, 15) every 4 weeks (days 1-28) as 1 course." | 1.35 | [A partial response to S-1 as second-line chemotherapy in a patient with unresectable pancreatic cancer]. ( Egawa, T; Hayashi, S; Ito, Y; Mihara, K; Nagashima, A; Ohashi, M; Takahashi, T, 2009) |
| "We report a case of gastric cancer with ascites treated with chemotherapy." | 1.34 | [Case of advanced gastric cancer successfully treated with chemotherapy of weekly paclitaxel]. ( Arakawa, T; Fujii, K; Kaneda, K; Kawamura, C; Kayo, S; Mizuyama, Y; Nakagawa, H; Ueda, Y; Uno, H, 2007) |
| "In general, treatment for gastric cancer with peritoneal dissemination or recurrent gastric cancer is outside the scope of surgery." | 1.33 | [A case of a nonresected gastric cancer with peritoneal dissemination maintained on TS-1 and docetaxel combination chemotherapy with good QOL]. ( Kawasaki, H; Kobori, H; Maruyama, M; Sasaki, M; Seino, K; Shibata, S; Sugiyama, Y; Yamada, K, 2005) |
| "She was diagnosed as remnant gastric cancer with multiple bone metastasis and peritoneal dissemination." | 1.33 | [A case of remnant gastric cancer with multiple bone metastasis and peritoneal dissemination; efficacy of combination therapy of docetaxel and TS-1]. ( Hamai, Y; Hihara, J; Tanabe, K; Toge, T; Ukon, K; Yoshida, K, 2005) |
| "One case with type 4 gastric cancer who had right hydronephrosis and malignant abdominal ascites underwent curative resection after successful treatment with TS-1." | 1.33 | [Peritoneal dissemination of scirrhous type 4 gastric cancers]. ( Aoyagi, K; Imaizumi, T; Koufuji, K; Miyagi, M; Murakami, N; Shirouzu, K; Yano, S, 2005) |
| "In advanced gastric cancer, the frequency of relapses such as metastasis to the peritoneum is high." | 1.33 | [Prediction and treatment of peritoneal dissemination in gastric cancer]. ( Aratake, K; Itabashi, M; Kameoka, S; Mitsuhashi, M; Ogawa, S; Seshimo, A; Shirotani, N, 2005) |
| "We reported 2 cases with advanced gastric cancer, successfully treated with TS-1 and CDDP." | 1.33 | [Two cases of advanced gastric cancer, successfully treated with TS-1/CDDP combination chemotherapy--case report]. ( Ando, K; Ishihara, C; Ishiwa, N; Morinaga, S; Noguchi, Y; Ogoshi, T; Shotsu, M; Takeda, A; Yamamoto, Y; Yoshida, S; Yoshikawa, T, 2005) |
| " There were less severe adverse events concerning paclitaxel despite of the second line therapy of TS-1, and 80 percent of all therapeutic courses was at an outpatient clinic." | 1.33 | [Safety and efficacy of chemotherapy using TS-1 followed by paclitaxel for advanced or recurrent gastric cancer with peritoneal dissemination]. ( Banba, T; Hatakeyama, K; Kanda, T; Kosugi, S; Ohashi, M; Tanabe, T; Yajima, K, 2005) |
| "By a diagnosis of descending colon cancer, descending colon ablative operation and D1 lymph node dissection were performed on April 22, 2004." | 1.33 | [A case of peritoneal dissemination disappeared by CPT-11 + TS-1 combination chemotherapy]. ( Fujishima, M; Fukunaga, M; Furukawa, H; Imamura, H; Kawasaki, T; Kishimoto, T; Kondo, M; Masutani, S; Nakayama, T; Ooshiro, R; Takemoto, H; Tanaka, J; Tatsuta, M; Yamamoto, K, 2005) |
| "Paclitaxel was ineffective, and so we opted for weekly administration of low-dose CDDP combined with TS-1, which led to the third recovery." | 1.33 | [A case of gastric cancer with peritoneal dissemination who achieved five-year survival by successive treatments with TS-1 alone and in combination with other drugs]. ( Aiko, S; Ishizuka, T; Kumano, I; Maehara, T; Sakano, T; Sugiura, Y; Yoshizumi, Y, 2006) |
| "Upper GI endoscopy revealed type 3 gastric cancer from the anglus to the cardia." | 1.33 | [A case of nonresected gastric cancer with peritoneal dissemination maintained on TS-1, cisplatin (CDDP) and docetaxel combination chemotherapy with good QOL]. ( Kimura, H; Koyama, F, 2006) |
| "We report a case of gastric cancer with peritoneal recurrence that responded to chemotherapy with paclitaxel and TS-1." | 1.33 | [A case of recurrent gastric cancer with peritoneal dissemination successfully treated over 1 year 8 months with combined chemotherapy of paclitaxel and TS-1]. ( Aihara, T; Kim, C; Miki, H; Nakata, K; Ohzato, H; Okada, K; Okamura, S; Sugimoto, K; Takatsuka, Y; Takiuchi, D; Tamura, S; Tomita, N, 2006) |
| "The response of gastric cancer with peritoneal dissemination to systemic chemotherapy may be negatively affected by poor drug delivery due to the blood-peritoneal barrier." | 1.33 | Pharmacokinetics of S-1 in patients with peritoneal dissemination of gastric cancer. ( Hatori, S; Imada, T; Kunisaki, C; Oshima, T; Yamada, R, 2006) |
| "Further examination showed an advanced gastric cancer with peritoneal dissemination." | 1.33 | [A case of advanced gastric cancer with peritoneal dissemination responding remarkably to TS-1/CDDP combination chemotherapy]. ( Asagoe, K; Azechi, H; Inoue, F; Ishii, K; Katsurada, A; Kondo, M; Nishikawa, K; Nishiura, H; Nonami, M; Otani, Y; Saiga, T; Shigemori, M; Suwa, H; Tojo, M, 2006) |
| "Human gastric cancer cells (MKN-45) were injected into the peritoneal cavity of nude mice." | 1.32 | Prevention of peritoneal metastasis of human gastric cancer cells in nude mice by S-1, a novel oral derivative of 5-Fluorouracil. ( Fujiwara, Y; Monden, M; Mori, T; Takiguchi, S; Tamura, S; Yano, M; Yasuda, T, 2003) |
| "S-1 appears to be safe and highly active, with favorable longterm survival in patients with metastatic gastric cancer, particularly in those with diffuse-type histology and peritoneal metastasis." | 1.32 | Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: results from a post-marketing survey. ( Boku, N; Doi, T; Hamamoto, Y; Kawai, H; Mera, K; Muto, M; Nagashima, F; Ohtsu, A; Sano, Y; Yano, T; Yoshida, S, 2003) |
| "We treated a patient with gastric cancer considered to be unresectable due to peritoneal metastasis, who responded remarkably to treatment with TS-1." | 1.32 | [A case of peritoneal metastasis of gastric cancer responding to TS-1, administered for four consecutive weeks with two-week rests]. ( Adachi, I; Emoto, T; Fujii, M; Fujikawa, M; Kamei, A; Komaki, T; Naka, Y; Nezu, R; Yokota, T; Yoshikawa, K; Yoshioka, Y, 2003) |
| "After the 5th course, the stenosis of colon and ascites had disappeared in a barium enema and CT scan, respectively." | 1.32 | [A case of advanced type 4 gastric cancer with peritonitis dissemination, navel metastasis effectively treated with combined chemotherapy of biweekly paclitaxel (TXL) and TS-1]. ( Aikou, T; Arima, H; Hamada, N; Hokita, S; Ishigami, S; Maeda, S; Miyazono, F; Natsugoe, S; Takao, S; Takatori, H, 2003) |
| "An umbilical metastasis of gastric cancer is known as Sister Mary Joseph's nodule." | 1.32 | [A case of gastric cancer with umbilical metastasis that responded to TS-1 with low-dose cis-platinum]. ( Fukunaga, S; Hirakawa, K; Inoue, T; Ishikawa, T; Kato, Y; Nakata, B; Nishiguchi, Y; Ohira, M; Takashima, T; Yamagata, S; Yashiro, M, 2004) |
| "Although the prognosis of recurrent gastric cancer with peritoneal dissemination was extremely poor, this case might suggest a possibility that intensive therapies are useful in maintaining the quality of life and improving survival." | 1.32 | [A case of recurrent gastric cancer with peritoneal dissemination successfully treated with DJ stents against bilateral hydronephrosis and chemotherapy]. ( Ebisui, C; Fujimoto, T; Fukuchi, N; Hasuike, Y; Hayashi, N; Izawa, H; Sakita, I; Souma, I; Yoshida, T, 2004) |
| "We report three patients with recurrent gastric cancer responding to TS-1 therapy after combination chemotherapy with 5-fluorouracil, mitomycin C and cisplatin." | 1.31 | [Three cases of recurrent gastric cancer responding to TS-1 therapy following combination therapy with 5-fluorouracil, mitomycin C and cisplatin]. ( Hayashi, K; Iijima, S; Koyama, Y; Miyazawa, K; Morikawa, A; Murakami, M; Okabe, R; Ozaki, K; Sugiyama, A; Suzuki, A, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 92 (42.79) | 29.6817 |
| 2010's | 115 (53.49) | 24.3611 |
| 2020's | 8 (3.72) | 2.80 |
| Authors | Studies |
|---|---|
| Mei, Y | 1 |
| Shi, M | 1 |
| Zhu, Z | 2 |
| Yuan, H | 1 |
| Yan, C | 1 |
| Li, C | 1 |
| Feng, T | 1 |
| Yan, M | 1 |
| Zhang, J | 2 |
| Todaka, A | 1 |
| Nara, S | 1 |
| Motoi, F | 2 |
| Morinaga, S | 2 |
| Toshiyama, R | 1 |
| Higuchi, R | 1 |
| Konishi, M | 2 |
| Shirakawa, H | 1 |
| Tsumura, H | 1 |
| Okuyama, H | 1 |
| Nagano, H | 1 |
| Shioji, K | 1 |
| Sugimachi, K | 1 |
| Asagi, A | 1 |
| Mizuno, N | 1 |
| Furuse, J | 1 |
| Zhang, L | 1 |
| Wang, Y | 2 |
| Li, W | 1 |
| Yu, S | 1 |
| Li, Q | 2 |
| Yu, Y | 2 |
| Liu, T | 2 |
| Cui, Y | 2 |
| Kobayashi, D | 1 |
| Ishigami, H | 14 |
| Kanda, M | 1 |
| Tanaka, C | 1 |
| Yamaguchi, H | 8 |
| Kitayama, J | 13 |
| Kodera, Y | 5 |
| Yamaguchi, T | 4 |
| Takashima, A | 1 |
| Nagashima, K | 1 |
| Makuuchi, R | 1 |
| Aizawa, M | 1 |
| Ohashi, M | 6 |
| Tashiro, K | 1 |
| Yamada, T | 4 |
| Kinoshita, T | 2 |
| Hata, H | 1 |
| Kawachi, Y | 1 |
| Kawabata, R | 1 |
| Tsuji, T | 1 |
| Hihara, J | 2 |
| Sakamoto, T | 1 |
| Fukagawa, T | 1 |
| Katai, H | 3 |
| Higuchi, K | 1 |
| Boku, N | 7 |
| Naruse, T | 1 |
| Hirono, Y | 3 |
| Kurebayashi, H | 1 |
| Katayama, H | 2 |
| Sawai, K | 1 |
| Morikawa, M | 1 |
| Koneri, K | 1 |
| Tamaki, M | 1 |
| Murakami, M | 3 |
| Goi, T | 1 |
| Nakamura, M | 2 |
| Ojima, T | 1 |
| Katsuda, M | 1 |
| Hayata, K | 1 |
| Kitadani, J | 1 |
| Nakamori, M | 2 |
| Yamaue, H | 2 |
| Nishigaki, T | 2 |
| Oka, Y | 2 |
| Taniguchi, H | 1 |
| Takahashi, K | 6 |
| Kawagishi, S | 1 |
| Yamashita, M | 1 |
| Takeyama, H | 1 |
| Danno, K | 1 |
| Toyoda, Y | 1 |
| Tokunaga, T | 1 |
| Sugimoto, K | 10 |
| Yamamoto, H | 2 |
| Ikeda, K | 2 |
| Kano, K | 1 |
| Aoyama, T | 3 |
| Maezawa, Y | 1 |
| Nakajima, T | 4 |
| Sato, T | 2 |
| Oshima, T | 3 |
| Rino, Y | 4 |
| Masuda, M | 4 |
| Ogata, T | 5 |
| Cho, H | 7 |
| Yoshikawa, T | 11 |
| Satoh, Y | 1 |
| Kurihara, M | 1 |
| Yatomi, Y | 1 |
| Nakayama, I | 1 |
| Chin, K | 2 |
| Matsushima, T | 1 |
| Takahari, D | 4 |
| Ogura, M | 1 |
| Shinozaki, E | 1 |
| Suenaga, M | 1 |
| Ozaka, M | 1 |
| Wakatsuki, T | 1 |
| Ichimura, T | 1 |
| Hiroki, O | 1 |
| Yamaguchi, K | 5 |
| Shimaoka, H | 1 |
| Shibata, R | 1 |
| Hosoda, Y | 1 |
| Hirano, Y | 1 |
| Munechika, T | 1 |
| Yonemitsu, K | 1 |
| Ishii, Y | 2 |
| Okamoto, T | 1 |
| Maeno, H | 1 |
| Noritomi, T | 1 |
| Yoshida, T | 3 |
| Sueishi, K | 1 |
| Miura, S | 2 |
| Ueda, N | 2 |
| Fujita, H | 2 |
| Kinami, S | 2 |
| Nakano, Y | 2 |
| Kosaka, T | 2 |
| Sakata, N | 1 |
| Nishino, R | 1 |
| Shimomura, K | 2 |
| Furuke, Y | 1 |
| Tanaka, Y | 2 |
| Kumano, T | 1 |
| Komatsu, S | 1 |
| Imura, K | 1 |
| Ikeda, J | 2 |
| Taniguchi, F | 2 |
| Shioaki, Y | 2 |
| Nakatsugawa, Y | 1 |
| Matsuda, Y | 1 |
| Nakamura, T | 3 |
| Ueta, K | 1 |
| Hasegawa, H | 2 |
| Yamamoto, M | 7 |
| Kanaji, S | 1 |
| Yamashita, K | 2 |
| Oshikiri, T | 1 |
| Matsuda, T | 1 |
| Sumi, Y | 1 |
| Suzuki, S | 2 |
| Kakeji, Y | 1 |
| Shinkai, M | 3 |
| Imano, M | 5 |
| Chiba, Y | 2 |
| Hiraki, Y | 2 |
| Kato, H | 3 |
| Iwama, M | 2 |
| Shiraisi, O | 1 |
| Yasuda, A | 3 |
| Tsubaki, M | 3 |
| Nishida, S | 3 |
| Kimura, Y | 5 |
| Yasuda, T | 6 |
| Shiraishi, O | 1 |
| Saito, K | 2 |
| Isayama, H | 4 |
| Nakai, Y | 3 |
| Takahara, N | 2 |
| Ishigaki, K | 1 |
| Takeda, T | 1 |
| Hakuta, R | 1 |
| Saito, T | 1 |
| Uchino, R | 1 |
| Kishikawa, T | 1 |
| Hamada, T | 1 |
| Mizuno, S | 1 |
| Sasaki, T | 4 |
| Kogure, H | 3 |
| Matsubara, S | 1 |
| Yamamoto, N | 2 |
| Ijichi, H | 2 |
| Tateishi, K | 2 |
| Tada, M | 3 |
| Koike, K | 3 |
| Muroya, T | 1 |
| Wajima, N | 1 |
| Kubo, N | 2 |
| Yoshida, E | 1 |
| Akaishi, T | 1 |
| Umetsu, S | 1 |
| Wakasa, Y | 1 |
| Sato, K | 1 |
| Mitsuhashi, Y | 1 |
| Umemura, K | 1 |
| Ogasawara, H | 1 |
| Hara, Y | 2 |
| Hakamada, K | 1 |
| Okada, K | 12 |
| Kawanaka, S | 1 |
| Taniguchi, S | 1 |
| Adachi, S | 1 |
| Yoshioka, S | 1 |
| Ueshima, S | 2 |
| Higaki, N | 1 |
| Hayashida, H | 1 |
| Nezu, R | 2 |
| Kato, S | 2 |
| Nishikawa, K | 5 |
| Hirao, M | 3 |
| Hamakawa, T | 2 |
| Fujiwara, A | 1 |
| Maeda, S | 2 |
| Uemura, M | 1 |
| Miyake, M | 2 |
| Hama, N | 1 |
| Miyamoto, A | 2 |
| Miyazaki, M | 3 |
| Kato, T | 3 |
| Takami, K | 1 |
| Nakamori, S | 2 |
| Sekimoto, M | 2 |
| Hattori, Y | 1 |
| Nakauchi, M | 1 |
| Tsuru, Y | 1 |
| Amano, S | 1 |
| Goto, A | 1 |
| Tomatsu, M | 1 |
| Nakamura, K | 3 |
| Kikuchi, K | 1 |
| Kadoya, S | 1 |
| Inaba, K | 1 |
| Kato, Y | 2 |
| Hanai, T | 1 |
| Sugioka, A | 1 |
| Uyama, I | 1 |
| Noma, T | 1 |
| Takahashi, T | 7 |
| Miyazaki, Y | 2 |
| Kurokawa, Y | 4 |
| Tanaka, K | 4 |
| Makino, T | 1 |
| Nakajima, K | 6 |
| Yamasaki, M | 5 |
| Mori, M | 5 |
| Doki, Y | 7 |
| Terashima, M | 3 |
| Iwasaki, Y | 5 |
| Mizusawa, J | 2 |
| Ito, Y | 5 |
| Kaji, M | 3 |
| Yamada, M | 2 |
| Kurita, A | 2 |
| Takagi, M | 2 |
| Sano, T | 2 |
| Sasako, M | 2 |
| Arai, H | 2 |
| Iwasa, S | 1 |
| Kawahira, M | 1 |
| Yasui, H | 5 |
| Masuishi, T | 1 |
| Muro, K | 4 |
| Minashi, K | 2 |
| Hironaka, S | 3 |
| Fukuda, N | 1 |
| Nakajima, TE | 1 |
| Fushida, S | 3 |
| Kinoshita, J | 1 |
| Goda, F | 4 |
| Yagi, Y | 3 |
| Oyama, K | 2 |
| Sudo, Y | 2 |
| Watanabe, Y | 2 |
| Fujimura, T | 2 |
| Hamaguchi, T | 1 |
| Yoshimura, K | 1 |
| Ito, S | 4 |
| Fuse, N | 2 |
| Goto, M | 3 |
| Tanigawa, N | 1 |
| Shirao, K | 2 |
| Saito, M | 1 |
| Yano, K | 1 |
| Kamigaki, T | 1 |
| Goto, S | 1 |
| Emoto, S | 5 |
| Yamashita, H | 8 |
| Watanabe, T | 5 |
| Nishiwada, S | 1 |
| Watanabe, A | 1 |
| Ishioka, K | 1 |
| Mukogawa, T | 1 |
| Matsusaka, M | 1 |
| Ko, S | 1 |
| Ishikawa, H | 2 |
| Katayama, K | 1 |
| Nishino, T | 1 |
| Takahashi, Y | 2 |
| Tanaka, T | 4 |
| Okitsu, H | 1 |
| Okitsu, N | 1 |
| Kaisaki, S | 5 |
| Watanabe, K | 2 |
| Kawahara, H | 2 |
| Enomoto, H | 2 |
| Toyama, Y | 1 |
| Akiba, T | 2 |
| Yanaga, K | 2 |
| Nemoto, H | 1 |
| Uchiyama, M | 1 |
| Atsumi, Y | 1 |
| Hasegawa, S | 2 |
| Tamagawa, H | 1 |
| Yukawa, N | 1 |
| Imada, T | 3 |
| Kanazawa, Y | 1 |
| Fujita, I | 1 |
| Onodera, H | 1 |
| Uchida, E | 1 |
| Canbay, E | 2 |
| Mizumoto, A | 3 |
| Ichinose, M | 2 |
| Ishibashi, H | 2 |
| Sako, S | 1 |
| Hirano, M | 2 |
| Takao, N | 2 |
| Yonemura, Y | 4 |
| Ohnishi, T | 1 |
| Fujita, J | 1 |
| Morioka, E | 1 |
| Kaida, D | 1 |
| Ohno, Y | 1 |
| Tomita, Y | 1 |
| Noguchi, M | 1 |
| Funaki, H | 1 |
| Shirai, J | 2 |
| Fujikawa, H | 2 |
| Iwasaki, K | 2 |
| Tsuburaya, A | 8 |
| Sujishi, K | 2 |
| Osaragi, T | 2 |
| Yoneyama, K | 2 |
| Kasahara, A | 2 |
| Yamamoto, Y | 5 |
| Wada, Y | 2 |
| Ebisui, C | 4 |
| Kato, R | 2 |
| Makino, S | 2 |
| Takeoka, T | 1 |
| Yanagisawa, T | 3 |
| Okamura, S | 10 |
| Fukuchi, N | 3 |
| Murata, K | 3 |
| Yokouchi, H | 3 |
| Kinuta, M | 3 |
| Sasaki, K | 2 |
| Fujiwara, Y | 12 |
| Kishi, K | 1 |
| Motoori, M | 2 |
| Sugimura, K | 3 |
| Miyoshi, N | 3 |
| Akita, H | 3 |
| Gotoh, K | 3 |
| Takahashi, H | 4 |
| Marubashi, S | 1 |
| Noura, S | 3 |
| Ohue, M | 3 |
| Yano, M | 6 |
| Sakon, M | 3 |
| Tomoda, M | 1 |
| Hayashi, T | 3 |
| Tanabe, K | 2 |
| Morita, S | 2 |
| Miyashita, Y | 1 |
| Sakamoto, J | 1 |
| Naito, M | 1 |
| Aisu, N | 1 |
| Maki, K | 1 |
| Nakagawa, M | 1 |
| Yoshida, Y | 1 |
| Hoshino, S | 1 |
| Yamashita, Y | 3 |
| Zhang, ZD | 1 |
| Kong, Y | 1 |
| Yang, W | 1 |
| Zhang, B | 1 |
| Zhang, YL | 1 |
| Ma, EM | 1 |
| Liu, HX | 1 |
| Chen, XB | 1 |
| Hua, YW | 1 |
| Koga, H | 1 |
| Miyoshi, A | 1 |
| Nakamura, J | 1 |
| Ide, T | 1 |
| Kitahara, K | 1 |
| Noshiro, H | 1 |
| Yamamura, A | 1 |
| Ono, F | 1 |
| Hiraga, M | 1 |
| Omura, N | 1 |
| Takano, N | 1 |
| Sato, H | 1 |
| Toyama, S | 1 |
| Onochi, S | 1 |
| Ozamoto, Y | 1 |
| Togawa, T | 1 |
| Tatsuno, M | 1 |
| Ueda, S | 3 |
| Minami, Y | 1 |
| Osaki, T | 1 |
| Kuroda, H | 1 |
| Nagai, S | 1 |
| Watanabe, H | 1 |
| Takahashi, S | 2 |
| Kurisu, Y | 1 |
| Ikeguchi, M | 1 |
| Shiozaki, S | 1 |
| Satoh, D | 1 |
| Matsukawa, H | 1 |
| Mimura, N | 1 |
| Taguchi, K | 1 |
| Araki, H | 1 |
| Toshima, T | 1 |
| Miyake, S | 1 |
| Miyoshi, H | 1 |
| Yoshida, K | 2 |
| Choda, Y | 1 |
| Tokumoto, N | 1 |
| Kanazawa, T | 1 |
| Harano, M | 1 |
| Ojima, Y | 1 |
| Idani, H | 2 |
| Okajima, M | 1 |
| Ninomiya, M | 2 |
| Tsukamoto, T | 2 |
| Kanazawa, A | 1 |
| Shimizu, S | 2 |
| Sakae, M | 1 |
| Ohira, G | 1 |
| Yoshii, M | 1 |
| Ishikawa, A | 1 |
| Mori, Y | 2 |
| Kotsuka, M | 1 |
| Goto, W | 1 |
| Kurihara, S | 1 |
| Tashima, T | 1 |
| Deguchi, S | 1 |
| Tachimori, A | 1 |
| Tamamori, Y | 1 |
| Yamamoto, A | 1 |
| Inoue, T | 3 |
| Nishiguchi, Y | 2 |
| Kawada, J | 1 |
| Fujitani, K | 3 |
| Yamamoto, K | 4 |
| Fukui, A | 1 |
| Fushimi, H | 1 |
| Endo, S | 1 |
| Iwase, K | 2 |
| Harada, Y | 1 |
| Fukuda, Y | 1 |
| Haraguchi, N | 1 |
| Asaoka, T | 1 |
| Ikeda, M | 1 |
| Nushijima, Y | 1 |
| Iwai, N | 1 |
| Wakabayashi, N | 1 |
| Matsumoto, N | 1 |
| Morita, Y | 1 |
| Tanaka, N | 3 |
| Yoriki, H | 1 |
| Fujii, K | 2 |
| Takada, R | 1 |
| Takaya, H | 1 |
| Masuzawa, A | 1 |
| Takami, S | 1 |
| Kataoka, K | 1 |
| Kurahashi, S | 1 |
| Misawa, K | 1 |
| Niwa, Y | 2 |
| Yatabe, Y | 1 |
| Shimizu, Y | 2 |
| Miyata, H | 7 |
| Takiguchi, S | 9 |
| Ito, T | 1 |
| Hanafusa, N | 1 |
| Ushiku, H | 1 |
| Katada, N | 1 |
| Hosoda, K | 1 |
| Moriya, H | 1 |
| Mieno, H | 1 |
| Kikuchi, S | 2 |
| Hoshi, K | 1 |
| Watanabe, M | 1 |
| Nishina, T | 2 |
| Gotoh, M | 3 |
| Shimada, Y | 1 |
| Hamamoto, Y | 2 |
| Kawai, H | 2 |
| Nakayama, N | 1 |
| Amagai, K | 2 |
| Ohtsu, A | 3 |
| Bando, H | 1 |
| Yamada, Y | 2 |
| Tanabe, S | 1 |
| Sugimoto, N | 1 |
| Tsuji, A | 2 |
| Imamura, H | 3 |
| Tsuda, M | 1 |
| Fujii, H | 1 |
| Shimada, K | 2 |
| Miwa, H | 1 |
| Hamada, C | 1 |
| Hyodo, I | 1 |
| Cao, C | 1 |
| Kuang, M | 1 |
| Xu, W | 1 |
| Zhang, X | 1 |
| Chen, J | 1 |
| Tang, C | 1 |
| Hara, T | 1 |
| Omori, T | 2 |
| Kobayashi, S | 2 |
| Nakao, K | 1 |
| Shitara, K | 4 |
| Fukunari, H | 1 |
| Okajima, C | 1 |
| Watanabe, G | 1 |
| Kobayashi, R | 1 |
| Takiguchi, N | 1 |
| Nabeya, Y | 1 |
| Ikeda, A | 1 |
| Souda, H | 1 |
| Kainuma, O | 1 |
| Tonooka, T | 1 |
| Imanishi, S | 1 |
| Arimitsu, H | 1 |
| Chibana, T | 1 |
| Ishige, F | 1 |
| Saito, H | 2 |
| Suematsu, Y | 1 |
| Hiratsuka, M | 1 |
| Suda, H | 1 |
| Takahashi, M | 1 |
| Omori, K | 1 |
| Ishibashi, Y | 1 |
| Morita, A | 1 |
| Wakabayashi, K | 1 |
| Nakade, H | 1 |
| Matsumoto, S | 3 |
| Wakatsuki, K | 2 |
| Migita, K | 2 |
| Ito, M | 2 |
| Kunishige, T | 1 |
| Kitano, M | 1 |
| Nakatani, M | 1 |
| Nakajima, Y | 2 |
| Urano, S | 1 |
| Kakiuchi, Y | 1 |
| Takashima, H | 1 |
| Li, Y | 1 |
| Coccolini, F | 1 |
| Glehen, O | 1 |
| Sugarbaker, PH | 1 |
| Morris, D | 1 |
| Moran, B | 1 |
| Gonzaletz-Moreno, S | 1 |
| Deraco, M | 1 |
| Piso, P | 1 |
| Elias, D | 1 |
| Batlett, D | 1 |
| Verwaal, V | 1 |
| Mahtem, H | 1 |
| Ibuki, Y | 1 |
| Yoshimitsu, M | 1 |
| Emi, M | 1 |
| Mukaida, H | 1 |
| Hirabayashi, N | 1 |
| Kagimoto, A | 1 |
| Kaneko, M | 2 |
| Takiyama, W | 1 |
| Suzuki, K | 1 |
| Yajima, K | 2 |
| Yuu, K | 1 |
| Oohinata, R | 1 |
| Amaki, M | 1 |
| Ilhan, E | 1 |
| Alemdar, A | 1 |
| Ureyen, O | 1 |
| Bas, K | 1 |
| Asakage, M | 1 |
| Satoi, S | 1 |
| Fujii, T | 1 |
| Yanagimoto, H | 1 |
| Kurata, M | 1 |
| Yamada, S | 1 |
| Yamamoto, T | 2 |
| Mizuma, M | 1 |
| Honda, G | 1 |
| Unno, M | 1 |
| Kon, M | 1 |
| Ishiguro, T | 1 |
| Fukuchi, M | 1 |
| Ogura, T | 1 |
| Muta, Y | 1 |
| Mochiki, E | 1 |
| Ishida, H | 2 |
| Tokunaga, Y | 1 |
| Sasaki, H | 2 |
| Saitou, T | 1 |
| Matsutani, T | 1 |
| Mizutani, T | 1 |
| Miyamoto, M | 1 |
| Maruyama, H | 1 |
| Yokoyama, T | 2 |
| Yanagi, K | 1 |
| Matsushita, A | 1 |
| Kashiwabara, M | 1 |
| Matsuda, A | 1 |
| Nishi, Y | 1 |
| Sasajima, K | 1 |
| Tajiri, T | 1 |
| Tokunaga, M | 1 |
| Tanabe, Y | 1 |
| Nasu, T | 1 |
| Abe, Y | 1 |
| Mitsuyama, S | 1 |
| Toyoshima, S | 1 |
| Ina, K | 2 |
| Kataoka, T | 2 |
| Takeuchi, Y | 1 |
| Fukuoka, T | 1 |
| Miwa, T | 1 |
| Nishio, T | 2 |
| Furuta, R | 2 |
| Masaki, A | 2 |
| Mori, F | 1 |
| Kayukawa, S | 2 |
| Nagao, S | 2 |
| Ando, T | 2 |
| Goto, H | 2 |
| Lee, JL | 1 |
| Kang, YK | 1 |
| Kang, HJ | 1 |
| Lee, KH | 1 |
| Zang, DY | 1 |
| Ryoo, BY | 1 |
| Kim, JG | 1 |
| Park, SR | 1 |
| Kang, WK | 1 |
| Shin, DB | 1 |
| Ryu, MH | 1 |
| Chang, HM | 1 |
| Kim, TW | 1 |
| Baek, JH | 1 |
| Min, YJ | 1 |
| Tanabe, D | 1 |
| Kondou, K | 1 |
| Uchiyama, T | 1 |
| Noda, K | 1 |
| Tamura, S | 11 |
| Miki, H | 8 |
| Miyake, T | 1 |
| Yoshimura, M | 2 |
| Suzuki, R | 4 |
| Nakahira, S | 5 |
| Nakata, K | 7 |
| Takatsuka, Y | 8 |
| Yamazaki, M | 2 |
| Nishida, T | 3 |
| Nunobe, S | 1 |
| Iwanaga, T | 3 |
| Iwagami, S | 1 |
| Matsumoto, H | 3 |
| Nakano, D | 3 |
| Sugimoto, T | 1 |
| Itakura, T | 1 |
| Uesaka, K | 1 |
| Otani, K | 3 |
| Kamei, T | 3 |
| Soma, D | 3 |
| Miyato, H | 3 |
| Hidemura, A | 3 |
| Nagawa, H | 3 |
| Kato, M | 2 |
| Kimura, H | 2 |
| Mukawa, A | 1 |
| Kumagai, K | 1 |
| Saikawa, Y | 3 |
| Fukuda, K | 2 |
| Ito, R | 1 |
| Igarashi, T | 1 |
| Tsuwano, S | 1 |
| Nakamura, R | 3 |
| Takeuchi, H | 1 |
| Kitagawa, Y | 2 |
| Kitajima, M | 3 |
| Satoh, G | 1 |
| Marusasa, T | 1 |
| Konishi, N | 1 |
| Ochiai, T | 2 |
| Nishimura, K | 1 |
| Futagawa, S | 1 |
| Okabe, H | 1 |
| Obama, K | 1 |
| Hosogi, H | 1 |
| Sakai, Y | 1 |
| Seshimo, K | 1 |
| Kanagawa, T | 1 |
| Oishi, M | 1 |
| Kodera, M | 1 |
| Yamamura, M | 1 |
| Katoh, H | 2 |
| Ikeda, H | 1 |
| Yokomichi, N | 1 |
| Kobayashi, K | 1 |
| Takita, K | 1 |
| Koizumi, W | 1 |
| Takiuchi, H | 3 |
| Komatsu, Y | 1 |
| Uji, K | 2 |
| Yoshida, A | 2 |
| Yoshioka, Y | 3 |
| Egawa, C | 3 |
| Asami, S | 1 |
| Kubo, S | 1 |
| Kurose, Y | 1 |
| Nojima, H | 1 |
| Yoshioka, T | 1 |
| Muro, M | 1 |
| Kumano, K | 1 |
| Hirata, M | 1 |
| Yamashita, T | 1 |
| Kin, H | 1 |
| Takakura, N | 1 |
| Kametaka, H | 1 |
| Makino, H | 1 |
| Koyama, T | 1 |
| Seike, K | 1 |
| Egawa, T | 1 |
| Mihara, K | 1 |
| Hayashi, S | 2 |
| Nagashima, A | 1 |
| Kubo, H | 1 |
| Kijima, T | 1 |
| Kitahara, M | 1 |
| Tada, K | 1 |
| Miyahara, M | 1 |
| Machida, H | 1 |
| Tominaga, K | 1 |
| Yano, H | 1 |
| Shimokawa, T | 2 |
| Tsujinaka, T | 1 |
| Furukawa, H | 4 |
| Murayama, Y | 1 |
| Sano, I | 1 |
| Doi, Y | 1 |
| Iwasaki, R | 1 |
| Chatani, T | 1 |
| Horiki, M | 1 |
| Kitada, M | 1 |
| Okuno, M | 1 |
| Kondo, S | 1 |
| Fukuda, H | 1 |
| Kashihara, T | 1 |
| Kawaguchi, M | 1 |
| Asada, Y | 1 |
| Terada, T | 1 |
| Takehara, A | 1 |
| Munemoto, Y | 1 |
| Fujisawa, K | 1 |
| Mitsui, T | 1 |
| Iida, Y | 1 |
| Tanemura, H | 2 |
| Oshita, H | 1 |
| Hatoh, T | 1 |
| Adachi, T | 1 |
| Matsui, K | 1 |
| Mochizuki, Y | 2 |
| Kojima, T | 3 |
| Nakanishi, H | 2 |
| Yamamura, Y | 2 |
| Sasahira, N | 2 |
| Hirano, K | 2 |
| Tsujino, T | 1 |
| Omata, M | 1 |
| Moon, JH | 1 |
| Takeno, A | 2 |
| Yamazaki, K | 1 |
| Taku, K | 1 |
| Yokota, T | 2 |
| Machida, N | 1 |
| Wakahara, T | 1 |
| Toyokawa, A | 2 |
| Tomono, A | 1 |
| Tani, S | 2 |
| Yamamichi, T | 1 |
| Nishioka, N | 1 |
| Gon, H | 2 |
| Kanemitsu, K | 2 |
| Okuda, T | 2 |
| Hamabe, Y | 1 |
| Iwasaki, T | 2 |
| Ishida, T | 3 |
| Akagi, T | 1 |
| Etoh, T | 1 |
| Eguchi, H | 1 |
| Hiroishi, K | 1 |
| Ueda, Y | 3 |
| Yasuda, K | 1 |
| Noguchi, T | 2 |
| Shiraishi, N | 1 |
| Kitano, S | 1 |
| Shikano, T | 2 |
| Hattori, K | 1 |
| Hachisuka, T | 1 |
| Mori, T | 4 |
| Shinohara, M | 1 |
| Miyauchi, M | 1 |
| Sadahiro, S | 1 |
| Suzuki, T | 1 |
| Maeda, Y | 1 |
| Tanaka, A | 1 |
| Kanoda, H | 1 |
| Kamijo, A | 1 |
| Kanemura, T | 1 |
| Yanai, A | 1 |
| Kobayashi, M | 1 |
| Kadono, M | 1 |
| Ohinata, R | 2 |
| Shoji, T | 1 |
| Kurita, N | 2 |
| Shimada, M | 1 |
| Iwata, T | 1 |
| Nishioka, M | 1 |
| Morimoto, S | 1 |
| Yoshikawa, K | 2 |
| Higashijima, J | 1 |
| Miyatani, T | 1 |
| Nakao, T | 1 |
| Zaima, C | 1 |
| Kanai, M | 1 |
| Ishikawa, S | 1 |
| Kawaguchi, Y | 1 |
| Masui, T | 2 |
| Nishimura, T | 1 |
| Yanagihara, K | 1 |
| Chiba, T | 1 |
| Mimori, T | 1 |
| Sakuma, T | 1 |
| Deguchi, R | 1 |
| Takashimizu, S | 1 |
| Ogasawara, F | 1 |
| Numata, M | 1 |
| Ohtani, Y | 1 |
| Sato, S | 1 |
| Mine, T | 1 |
| Iwata, Y | 1 |
| Masubuchi, M | 1 |
| Matsumura, T | 1 |
| Oomoto, K | 1 |
| Horiba, T | 1 |
| Sato, E | 1 |
| Orihara, A | 1 |
| Sonoda, H | 1 |
| Hamada, J | 1 |
| Itokawa, Y | 1 |
| Ueshima, Y | 1 |
| Takashina, K | 1 |
| Lee, C | 1 |
| Kuwabara, H | 1 |
| Mikayama, Y | 1 |
| Kitasato, Y | 1 |
| Yasunaga, M | 1 |
| Nakayama, M | 2 |
| Akasu, G | 1 |
| Yoshitomi, M | 1 |
| Mikagi, K | 1 |
| Kawahara, R | 1 |
| Hisaka, T | 1 |
| Horiuchi, H | 1 |
| Kinoshita, H | 1 |
| Okabe, Y | 1 |
| Narita, T | 1 |
| Suzuki, A | 2 |
| Hashizume, E | 1 |
| Yajima, M | 1 |
| Mizota, A | 1 |
| Matsuo, K | 1 |
| Sato, Y | 1 |
| Kondo, C | 1 |
| Ura, T | 1 |
| Tajika, M | 1 |
| Okumura, K | 1 |
| Shiogai, Y | 1 |
| Kodama, M | 1 |
| Mekata, E | 1 |
| Tan, T | 1 |
| Enomoto, K | 1 |
| Takayama, T | 1 |
| Ohno, T | 1 |
| Horiguchi, N | 1 |
| Asukai, K | 1 |
| Miura, A | 1 |
| Koguchi, H | 1 |
| Matsunaga, S | 1 |
| Togawa, S | 1 |
| Hasegawa, I | 1 |
| Sakakibara, K | 1 |
| Oneyama, M | 1 |
| Sekikawa, K | 1 |
| Kitamura, M | 1 |
| Kawahara, Y | 1 |
| Ohta, R | 1 |
| Hirata, Y | 1 |
| Shimoda, Y | 1 |
| Kawakubo, K | 1 |
| Iwakura, S | 1 |
| Shimamoto, T | 1 |
| Higashiguchi, T | 1 |
| Nakase, T | 1 |
| Kunimoto, H | 1 |
| Aoki, Y | 1 |
| Peng, YF | 1 |
| Itoh, T | 1 |
| Nishikawa, M | 1 |
| Satou, T | 1 |
| Inoue, K | 1 |
| Imamoto, H | 2 |
| Takeyama, Y | 1 |
| Okuno, K | 1 |
| Shiozaki, H | 1 |
| Shimoyama, S | 1 |
| Kiyokawa, T | 1 |
| Nishida, M | 1 |
| Seto, Y | 1 |
| Chen, Y | 1 |
| Feng, Y | 1 |
| Muguruma, K | 1 |
| Tanaka, H | 1 |
| Sakurai, K | 1 |
| Kimura, K | 1 |
| Nagahara, H | 1 |
| Amano, R | 1 |
| Noda, E | 1 |
| Maeda, K | 1 |
| Sawada, T | 3 |
| Ohira, M | 4 |
| Hirakawa, K | 5 |
| Ohwada, Y | 1 |
| Wang, X | 1 |
| Wang, ML | 1 |
| Zhou, LY | 1 |
| Lu, XY | 1 |
| Yang, JF | 1 |
| Yu, HG | 1 |
| Iizuka, R | 1 |
| Kakihara, N | 1 |
| Matsumura, H | 1 |
| Takenaka, A | 1 |
| Imazu, H | 1 |
| Ochiai, M | 1 |
| Sakurai, Y | 1 |
| Matsubara, T | 1 |
| Nozoe, Y | 1 |
| Monden, M | 4 |
| Ito, K | 1 |
| Akiyama, S | 1 |
| Nakao, A | 1 |
| Tatematsu, M | 1 |
| Baba, H | 1 |
| Endo, K | 1 |
| Ikeda, Y | 1 |
| Toh, Y | 1 |
| Kohnoe, S | 1 |
| Okamura, T | 1 |
| Nagashima, F | 1 |
| Muto, M | 2 |
| Sano, Y | 1 |
| Mera, K | 1 |
| Yano, T | 2 |
| Doi, T | 2 |
| Yoshida, S | 3 |
| Konishi, K | 2 |
| Kobayashi, O | 3 |
| Sairenji, M | 2 |
| Motohashi, H | 2 |
| Usuki, H | 2 |
| Ishimura, K | 1 |
| Yachida, S | 2 |
| Hagiike, M | 2 |
| Okano, K | 1 |
| Izuishi, K | 2 |
| Karasawa, Y | 2 |
| Maeta, H | 2 |
| Tsujitani, S | 2 |
| Kaibara, N | 1 |
| Fujiwara, H | 2 |
| Takagane, A | 1 |
| Abe, K | 1 |
| Irinoda, T | 1 |
| Nakaya, T | 1 |
| Yonezawa, H | 1 |
| Kanzaki, N | 1 |
| Ohtani, S | 2 |
| Nemoto, T | 1 |
| Hoshino, Y | 1 |
| Kogure, M | 1 |
| Naka, Y | 1 |
| Fujikawa, M | 1 |
| Fujii, M | 1 |
| Emoto, T | 1 |
| Komaki, T | 1 |
| Adachi, I | 1 |
| Kamei, A | 1 |
| Hokita, S | 1 |
| Takatori, H | 1 |
| Ishigami, S | 1 |
| Miyazono, F | 1 |
| Arima, H | 1 |
| Natsugoe, S | 1 |
| Takao, S | 1 |
| Aikou, T | 1 |
| Hamada, N | 1 |
| Nakagawa, A | 1 |
| Ichiki, M | 1 |
| Sai, K | 1 |
| Sugawara, H | 1 |
| Wada, H | 1 |
| Kozuma, Y | 1 |
| Kittaka, N | 2 |
| Kim, T | 1 |
| Takiuchi, D | 4 |
| Aihara, T | 3 |
| Fukunaga, M | 2 |
| Ozato, H | 1 |
| Tomita, N | 4 |
| Kitamura, Y | 1 |
| Hayashi, K | 3 |
| Sasagawa, T | 1 |
| Oguma, H | 1 |
| Takasaki, K | 1 |
| Shima, Y | 1 |
| Horimi, T | 1 |
| Nishioka, Y | 1 |
| Okabayashi, T | 1 |
| Hamada, M | 1 |
| Ishikawa, T | 3 |
| Shibuya, Y | 1 |
| Sakurama, K | 1 |
| Nishie, M | 1 |
| Iwata, J | 1 |
| Arai, W | 1 |
| Hosoya, Y | 1 |
| Saito, S | 1 |
| Hirashima, Y | 2 |
| Hyodo, M | 1 |
| Yasuda, Y | 1 |
| Nagai, H | 1 |
| Shirasaka, T | 1 |
| Takashima, T | 2 |
| Yamagata, S | 2 |
| Fukunaga, S | 1 |
| Yashiro, M | 2 |
| Nakata, B | 3 |
| Taguchi, S | 1 |
| Osugi, H | 1 |
| Takemura, M | 1 |
| Lee, S | 1 |
| Nishizawa, S | 1 |
| Iwasaki, H | 1 |
| Mikata, S | 1 |
| Higaki, J | 1 |
| Yoshikawa, S | 1 |
| Ide, H | 1 |
| Kim, H | 1 |
| Oimatsu, N | 1 |
| Inayama, M | 1 |
| Kamiike, W | 1 |
| Souma, I | 1 |
| Hayashi, N | 1 |
| Izawa, H | 1 |
| Sakita, I | 1 |
| Hasuike, Y | 1 |
| Fujimoto, T | 1 |
| Yamada, K | 1 |
| Sugiyama, Y | 1 |
| Seino, K | 1 |
| Kobori, H | 1 |
| Maruyama, M | 1 |
| Shibata, S | 1 |
| Kawasaki, H | 1 |
| Sasaki, M | 1 |
| Kuriyama, H | 1 |
| Nonaka, T | 1 |
| Sawatari, T | 1 |
| Tsuboi, H | 1 |
| Akanuma, M | 1 |
| Hata, Y | 1 |
| Fujita, S | 1 |
| Ooka, M | 1 |
| Okajima, S | 1 |
| Tsuboi, Y | 1 |
| Akamoto, S | 1 |
| Okada, S | 1 |
| Hamai, Y | 1 |
| Ukon, K | 1 |
| Toge, T | 1 |
| Komoto, M | 1 |
| Nomura, S | 1 |
| Kubota, T | 2 |
| Akatsu, Y | 1 |
| Yoshida, M | 2 |
| Otani, Y | 2 |
| Kumai, K | 2 |
| Koufuji, K | 1 |
| Aoyagi, K | 1 |
| Yano, S | 1 |
| Murakami, N | 1 |
| Miyagi, M | 1 |
| Imaizumi, T | 1 |
| Shirouzu, K | 1 |
| Seshimo, A | 1 |
| Mitsuhashi, M | 1 |
| Aratake, K | 1 |
| Ogawa, S | 1 |
| Itabashi, M | 1 |
| Shirotani, N | 1 |
| Kameoka, S | 1 |
| Ishihara, C | 1 |
| Noguchi, Y | 1 |
| Ando, K | 1 |
| Shotsu, M | 1 |
| Ishiwa, N | 1 |
| Takeda, A | 1 |
| Ogoshi, T | 1 |
| Endou, Y | 1 |
| Tochiori, S | 1 |
| Bando, E | 1 |
| Kawamura, T | 1 |
| Shimada, T | 1 |
| Miyamoto, K | 1 |
| Tanaka, M | 1 |
| Kanda, T | 1 |
| Banba, T | 1 |
| Tanabe, T | 1 |
| Kosugi, S | 1 |
| Hatakeyama, K | 1 |
| Takemoto, H | 1 |
| Ooshiro, R | 1 |
| Fujishima, M | 1 |
| Tanaka, J | 1 |
| Kondo, M | 3 |
| Kishimoto, T | 1 |
| Nakayama, T | 1 |
| Masutani, S | 1 |
| Tatsuta, M | 1 |
| Kawasaki, T | 1 |
| Koshikawa, K | 1 |
| Kiriyama, K | 1 |
| Wada, M | 1 |
| Taniguchi, K | 1 |
| Suenaga, H | 1 |
| Kanazawa, S | 1 |
| Seo, A | 1 |
| Tokura, N | 1 |
| Honda, R | 1 |
| Kase, H | 1 |
| Teramoto, T | 1 |
| Tendo, M | 1 |
| Nakazawa, K | 1 |
| Yamada, N | 1 |
| Aiko, S | 1 |
| Yoshizumi, Y | 1 |
| Sugiura, Y | 1 |
| Ishizuka, T | 1 |
| Sakano, T | 1 |
| Kumano, I | 1 |
| Maehara, T | 1 |
| Kim, C | 2 |
| Ohzato, H | 2 |
| Koyama, F | 1 |
| Kitajima, K | 1 |
| Sugi, S | 1 |
| Kagawa, K | 1 |
| Kumamoto, T | 1 |
| Murakami, K | 1 |
| Fujioka, T | 1 |
| Yamada, R | 1 |
| Hatori, S | 1 |
| Kunisaki, C | 1 |
| Kanamaru, T | 1 |
| Ishizone, S | 1 |
| Maruta, F | 1 |
| Koide, N | 1 |
| Sugiyama, A | 2 |
| Nakayama, J | 1 |
| Miyagawa, S | 1 |
| Munakata, M | 1 |
| Sakata, Y | 1 |
| Ishii, E | 1 |
| Wada, R | 1 |
| Nishiura, H | 1 |
| Ishii, K | 1 |
| Nonami, M | 1 |
| Shigemori, M | 1 |
| Katsurada, A | 1 |
| Azechi, H | 1 |
| Tojo, M | 1 |
| Asagoe, K | 1 |
| Inoue, F | 1 |
| Suwa, H | 1 |
| Saiga, T | 1 |
| Hara, A | 1 |
| Tsunemi, S | 1 |
| Izumi, N | 1 |
| Iwamoto, S | 1 |
| Ichikawa, D | 1 |
| Okamoto, K | 1 |
| Sakakura, C | 1 |
| Otsuji, E | 1 |
| Sonoyama, T | 1 |
| Hagiwara, A | 1 |
| Yamagishi, H | 1 |
| Sugiyama, S | 1 |
| Miyade, Y | 1 |
| Murakami, S | 1 |
| Samejima, R | 1 |
| Sumi, K | 1 |
| Hidaka, K | 1 |
| Uno, H | 1 |
| Kayo, S | 1 |
| Kawamura, C | 1 |
| Mizuyama, Y | 1 |
| Kaneda, K | 1 |
| Nakagawa, H | 1 |
| Arakawa, T | 1 |
| Hosokawa, A | 1 |
| Sugiyama, T | 1 |
| Hattori, S | 1 |
| Okuda, N | 1 |
| Ichikawa, K | 1 |
| Yamaoka, T | 1 |
| Katou, T | 1 |
| Wada, N | 1 |
| Mizutani, S | 1 |
| Oyama, T | 1 |
| Uchikoshi, F | 1 |
| Yoshidome, K | 1 |
| Tori, M | 1 |
| Hiraoka, K | 1 |
| Yamagami, Y | 1 |
| Nakahara, M | 1 |
| Fukushima, N | 1 |
| Nashimoto, A | 1 |
| Ohta, T | 1 |
| Narahara, H | 1 |
| Yamaki, S | 1 |
| Iwata, S | 1 |
| Ohtsuka, K | 1 |
| Kitaoka, A | 1 |
| Masumoto, H | 1 |
| Takayanagi, H | 1 |
| Karaki, H | 1 |
| Suzuki, H | 1 |
| Yamamori, H | 1 |
| Sugano, I | 1 |
| Matsuyama, A | 1 |
| Kameyama, T | 1 |
| Okamoto, M | 1 |
| Okazaki, J | 1 |
| Utsunomiya, T | 1 |
| Tsutsui, S | 1 |
| Iwahashi, M | 1 |
| Tani, M | 1 |
| Sakaguchi, S | 1 |
| Ueda, K | 1 |
| Ichiro, M | 1 |
| Nishino, E | 1 |
| Tanimura, H | 1 |
| Inaba, Y | 1 |
| Watabe, S | 1 |
| Ohe, S | 1 |
| Kamio, Y | 1 |
| Koyama, M | 1 |
| Chiba, M | 1 |
| Kanari, M | 1 |
| Morikawa, A | 1 |
| Okabe, R | 1 |
| Miyazawa, K | 1 |
| Iijima, S | 1 |
| Ozaki, K | 1 |
| Koyama, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I/II, Single-center, Single-arm, Open-label Study of Nanoparticle Albumin-bound-paclitaxel (Nab-PTX) Plus S-1 and Sintilimab as Adjuvant Therapy in Patients With Stage IIIC Gastric Cancer[NCT04781413] | Phase 1/Phase 2 | 38 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| Docetaxel, Oxaliplatin, Fluorouracil (FLOT Regimen) Combined With Teriprizumab (PD-1) in the First-line Treatment of Patients With Advanced Gastric Cancer and Peritoneal Metastasis: an Open, One-arm, Exploratory Study[NCT04886193] | 20 participants (Anticipated) | Interventional | 2021-04-16 | Recruiting | |||
| The Exploratory Study of Conversion Surgery for Apatinib in Combination With Oxaliplatin/S-1(SOX) for Patients With Unresectable Gastric Cancer[NCT03007446] | Phase 2 | 20 participants (Anticipated) | Interventional | 2016-11-30 | Recruiting | ||
| Comparison of Efficacy and Tolerance Between Combination Therapy and Monotherapy as a First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer; Multicenter Randomized Phase 3 Study[NCT02114359] | Phase 3 | 111 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| Phase III Study of Adjuvant Capecitabine vs Observation Alone in Curatively Resected Stage IB (by AJCC 6th Edition) Gastric Cancer(KCSG ST14-05)[NCT01917552] | Phase 3 | 870 participants (Anticipated) | Interventional | 2013-08-19 | Recruiting | ||
| Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320] | Phase 2 | 200 participants (Actual) | Interventional | 2015-10-05 | Active, not recruiting | ||
| Phase III Trial of S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer[NCT01671449] | Phase 3 | 338 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| Phase 1 Study of Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) and Electrostatic PIPAC (ePIPAC) With Paclitaxel for Peritoneal Carcinomatosis - PIPAC2 Study[NCT05395910] | Phase 1 | 36 participants (Anticipated) | Interventional | 2022-10-31 | Recruiting | ||
| Phase 1 Study of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Oxaliplatin. Phase 1 Study of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Oxaliplatin and in Combination With Nivolumab in Patients With Peritoneal Carcinomat[NCT03172416] | Phase 1 | 21 participants (Anticipated) | Interventional | 2017-04-12 | Recruiting | ||
| Feasibility Study of Intraperitoneal Paclitaxel With Oxaliplatin and Capecitabine in Patients With Advanced Gastric Cancer[NCT01739894] | Phase 2 | 20 participants (Anticipated) | Interventional | 2013-01-31 | Recruiting | ||
| A Phase II Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Combined With Sintilimab in Gastric Cancer With Peritoneal Metastasis[NCT05648487] | Phase 2 | 46 participants (Anticipated) | Interventional | 2023-01-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13 reviews available for oxonic acid and Peritoneal Carcinomatosis
| Article | Year |
|---|---|
[A Case of Remnant Gastric Cancer That Completely Responded to Neoadjuvant S-1 and Cisplatin Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastrectomy; Hum | 2017 |
[A Case of QOL Improvement after Intestinal Stenosis Due to Peritoneal Dissemination of Gastric Cancer in Elderly Patients].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Fe | 2017 |
[Curative resection of a case of advanced gastric cancer with peritoneal dissemination responding well to combination chemotherapy of docetaxel,cisplatin and S-1].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxe | 2013 |
[A case of jejnal cancer who was controlled peritoneal metastasis, successfully by combination therapy with docetaxel and S-1].
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Humans; Jejunal Neopla | 2013 |
[A case of effective treatment with S-1/gemcitabine chemotherapy and resection for advanced pancreatic cancer with peritoneal dissemination].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug | 2014 |
[A case of highly advanced gastric cancer with peritoneal dissemination -- a histological CR to S-1 and CDDP combination chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Humans; Male; Middle A | 2015 |
Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asian | 2015 |
[Long-Term Disease-Free Survival through Postoperative Chemotherapy in a Case of Gastric Cancer with Peritoneal Dissemination].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Doceta | 2015 |
A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytoreduction Surgical Procedures; Doceta | 2016 |
The Importance of Extensive Intraoperative Peritoneal Lavage as a Promising Method in Patients with Gastric Cancer Showing Positive Peritoneal Cytology Without Overt Peritoneal Metastasis and Other Therapeutic Approaches.
Topics: Antimetabolites, Antineoplastic; Drug Combinations; Humans; Infusions, Parenteral; Intraoperative Ca | 2017 |
Aggressive recurrence of gastric cancer as a granulocyte-colony-stimulating factor-producing tumor.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biopsy; Chemotherapy, Adjuvant; Drug Combinations; | 2010 |
[A case of scirrhous gastric carcinoma with peritoneal dissemination which was treated by curative gastrectomy after S-1/CDDP chemotherapy].
Topics: Adenocarcinoma, Scirrhous; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinati | 2010 |
[A case of peritoneal dissemination that exhibited a complete response to systemic chemotherapy following the resection of primary colon cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colostomy; Combined Modality Ther | 2012 |
37 trials available for oxonic acid and Peritoneal Carcinomatosis
| Article | Year |
|---|---|
Addition of sintilimab to nanoparticle albumin-bound paclitaxel and S-1 as adjuvant therapy in stage IIIC gastric cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal, Humanized; Antineoplas | 2022 |
Phase I Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Cisplatin for Gastric Cancer with Peritoneal Metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; H | 2020 |
Phase 1 Study of Combined Chemotherapy of Nab-Paclitaxel, S-1, and Oxaliplatin for Gastric Cancer with Peritoneal Metastasis (NSOX Study).
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Dr | 2021 |
The survival and prognosticators of peritoneal cytology-positive gastric cancer patients who received upfront gastrectomy and subsequent S-1 chemotherapy.
Topics: Aged; Disease-Free Survival; Drug Combinations; Female; Gastrectomy; Humans; Lymphatic Metastasis; M | 2017 |
Retrospective comparison of S-1 plus cisplatin versus S-1 monotherapy for the treatment of advanced gastric cancer patients with positive peritoneal cytology but without gross peritoneal metastasis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Combina | 2017 |
Intraperitoneal and Systemic Chemotherapy for Patients with Gastric Cancer with Peritoneal Metastasis: A Phase II Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Follow-Up Studies; H | 2018 |
A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug | 2019 |
Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG0501).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2019 |
Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, | 2013 |
A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis.
Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 2013 |
Low creatinine clearance is a risk factor for D2 gastrectomy after neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 2014 |
Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regime
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Drug Combin | 2016 |
Efficacy and safety of S-1 and oxaliplatin combination therapy in elderly patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; F | 2016 |
Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancr | 2017 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
[Clinical trials of neo-adjuvant chemotherapy for advanced gastric cancer with peritoneal dissemination].
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Drug Co | 2008 |
[Treatment for advanced gastric cancer with positive lavage cytology-systemic versus intraperitoneal chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Gastric Lavage | 2008 |
Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Fema | 2009 |
Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug | 2010 |
Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug | 2010 |
Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug | 2010 |
Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug | 2010 |
Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug | 2010 |
Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug | 2010 |
Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug | 2010 |
Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug | 2010 |
Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug | 2010 |
Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Follow-Up St | 2010 |
Phase II clinical trial of postoperative S-1 monotherapy for gastric cancer patients with free intraperitoneal cancer cells detected by real-time RT-PCR.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; D | 2010 |
Impact of S-1 in patients with gemcitabine-refractory pancreatic cancer in Japan.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Surviva | 2010 |
Feasibility study of S-1 and intraperitoneal docetaxel combination chemotherapy for gastric cancer with peritoneal dissemination.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; D | 2010 |
Phase I study of docetaxel, cisplatin and S-1 in patients with advanced gastric cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Femal | 2010 |
Intraperitoneal infusion of paclitaxel with S-1 for peritoneal metastasis of advanced gastric cancer: phase I study.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Ascitic Fluid; Drug Combinations; Female; H | 2011 |
[The updated treatment strategy for gastric cancer with peritoneal metastasis].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2012 |
A preliminary study of single intraperitoneal administration of paclitaxel followed by sequential systemic chemotherapy with S-1 plus paclitaxel for advanced gastric cancer with peritoneal metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Comb | 2012 |
Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehydroge | 2013 |
Randomized phase II study comparing paclitaxel with S-1 vs. S-1 as first-line treatment in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combin | 2013 |
Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2003 |
Combination chemotherapy of S-1 and low-dose cisplatin for advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cispla | 2003 |
Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2003 |
Pilot study of S-1 in patients with disseminated gastric cancer.
Topics: Administration, Oral; Adult; Aged; Drug Administration Schedule; Drug Combinations; Female; Humans; | 2003 |
[Neoadjuvant chemotherapy for gastric cancer with peritoneal dissemination].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Female; F | 2007 |
[A multi-centric phase I/II study of intraperitoneal docetaxel combined with S-1 for patients with peritoneal dissemination of gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Humans; Infusions, Par | 2007 |
Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302).
Topics: Adenocarcinoma; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Disease-Free | 2008 |
[The clinical effect of TS-1 in advanced and recurrent gastric cancer with peritoneal dissemination].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Femal | 2002 |
165 other studies available for oxonic acid and Peritoneal Carcinomatosis
| Article | Year |
|---|---|
Postoperative Treatment of Resectable Pancreatic Cancer With Positive Peritoneal Lavage Cytology: A Multicentre Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Ge | 2022 |
Efficacy of AS versus SOX regimen as first-line chemotherapy for gastric cancer patients with peritoneal metastasis: a real-world study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Gastrectomy; Humans; Oxaliplatin; | 2022 |
Efficacy of Postoperative Chemotherapy After Resection that Leaves No Macroscopically Visible Disease of Gastric Cancer with Positive Peritoneal Lavage Cytology (CY1) or Localized Peritoneum Metastasis (P1a): A Multicenter Retrospective Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2020 |
[A Long Term Survival Case of Gastric Cancer with Peritoneal Dissemination Responding to Intraperitoneal Chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Gastrectomy; Human | 2020 |
[A Case of Advanced Gastric Cancer with Peritoneal Metastasis Achieved Pathological Complete Response by Chemotherapy(SOX Regimen)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Gastrectomy; Humans | 2020 |
Peritoneal Lavage CEA mRNA Levels Predict Conversion Gastrectomy Outcomes after Induction Chemotherapy with Intraperitoneal Paclitaxel in Gastric Cancer Patients with Peritoneal Metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Combined Moda | 2017 |
[A Case of Unresectable Gastric Cancer with Multiple Metastases Responding to Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Humans; Liver Ne | 2017 |
[Advanced Gastric Cancer with Peritoneal Dissemination Treated with Conversion Surgery after S-1 and CDDP Chemotherapy - A Case Report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Humans; | 2018 |
Intraperitoneal Administration of Paclitaxel Followed by Paclitaxel, Cisplatin, and S-1 Chemotherapy for Cytology-positive Gastric Cancer: A Feasibility Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Feasibility Stud | 2018 |
[A Case of Advanced Gastric Cancer with Peritoneal Dissemination after Gastrectomy Effectively Treated with Combination Chemotherapy of Ramucirumab and Paclitaxel].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2018 |
[Three Cases of Advanced Gastric Cancer with Peritoneal Dissemination Successfully Treated with S-1 and Docetaxel Combination Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Female; Gastrect | 2018 |
[A Case of Peritoneal Dissemination of Metastatic Gastric Cancer with Successful Docetaxel and S-1 Combination Therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Gastrectomy; Humans; M | 2018 |
[A Case of Robot-Assisted Conversion Surgery for Gastric Cancer with Peritoneal Dissemination That Responded to Intravenous and Intraperitoneal Paclitaxel Combined with S-1 Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Gastrectomy; Humans | 2019 |
[Multi-Look Staging Laparoscopy and Conversion Surgery for Gastric Cancer with Peritoneal Metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Gastrectomy; Humans; Laparoscopy; | 2019 |
Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Ascites; Cisplatin; | 2019 |
Survival analysis of adjuvant chemotherapy with S-1 plus cisplatin for stage III gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations | 2014 |
A patient with scirrhous stomach cancer treated with combination of hyperthermotherapy and 5-aminolevulinic acid (ALA).
Topics: Adenocarcinoma, Scirrhous; Adult; Aminolevulinic Acid; Antineoplastic Combined Chemotherapy Protocol | 2013 |
[A case of AFP-producing gastric cancer with peritoneal metastasis treated effectively with chemotherapy, mainly using S-1 and trastuzumab].
Topics: Aged; alpha-Fetoproteins; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antine | 2013 |
[Approximately four years of survival benefits for a case of gastric cancer postoperative carcinomatous peritonitis by combined modality therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; | 2013 |
Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Combined | 2014 |
Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Combined | 2014 |
Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Combined | 2014 |
Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Combined | 2014 |
Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2013 |
Adjuvant chemotherapy with S-1 followed by docetaxel for gastric cancer and CY1P0 peritoneal metastasis after relatively curative surgery.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy | 2013 |
Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusio | 2014 |
[A case of gastric cancer with intensive peritoneal dissemination treated with long-term chemotherapy and surgery].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Drug Combinati | 2013 |
[A case of advanced gastric cancer with peritoneal dissemination recurrence after gastrectomy effectively treated with combination chemotherapy of S-1 and docetaxel].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Gastrectomy; Hum | 2013 |
[A case of rectal stenosis due to peritoneal dissemination from gastric cancer that was treated with chemoradiation therapy].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Chemoradiothe | 2013 |
[Repeated occlusion of the intraperitoneal access port for intraperitoneal chemotherapy in a patient with gastric cancer with peritoneal dissemination].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Humans; Male; Middle Aged; Oxonic | 2013 |
Usefulness of monthly chemotherapy for patients with unresectable metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2014 |
[A case of unresected gastric cancer that maintained long tumor dormancy by use of paclitaxel+S-1 combination therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; M | 2014 |
Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetu | 2014 |
[A case of a patient with gastric cancer and peritoneal dissemination who survived for more than 10 years after successful treatment with S-1].
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Female; Gastrectomy; | 2014 |
[A case of gastric adenosquamous carcinoma with peritoneal dissemination in which treatment with S-1 plus paclitaxel therapy resulted in improved long-term survival].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Adenosquamous; Chemotherapy, Adju | 2014 |
Clinical significance of cytological status of peritoneal lavage fluid during intraperitoneal chemotherapy for gastric cancer with overt peritoneal dissemination.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2015 |
[A case of gastric cancer with peritoneal dissemination successfully treated with low-dose S-1 or capecitabine chemotherapy for five years].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Combinations | 2014 |
[Long-term disease-free survival by S-1 therapy in a case of gastric cancer with peritoneal dissemination].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Surviv | 2014 |
[A case of intrahepatic cholangiocarcinoma with peritoneal dissemination treated successfully with surgical resection and adjuvant chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chemotherapy, | 2014 |
[A case of radical resection for pancreatic head cancer with peritoneal dissemination treated with combination chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Gemcitabine; | 2014 |
[A case of advanced gastric cancer successfully treated with second-line chemotherapy followed by curative conversion gastrectomy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug | 2014 |
[A case of successful treatment of peritoneal dissemination from gastric cancer with S-1/DOC chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Gastrectomy; Hum | 2014 |
[A recurrent gastric cancer with peritoneal metastasis 15 years after distal gastrectomy successfully treated with S-1 and weekly intravenous and intraperitoneal injections of Paclitaxel].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Combinations; Female; Gastrectom | 2015 |
Preoperative systemic and intraperitoneal chemotherapy consisting of S-1, cisplatin and docetaxel in patients with marginally resectable gastric cancer.
Topics: Adult; Aged; Cisplatin; Docetaxel; Drug Combinations; Drug-Related Side Effects and Adverse Reaction | 2015 |
Cell-free and concentrated ascites reinfusion therapy (CART) for management of massive malignant ascites in gastric cancer patients with peritoneal metastasis treated with intravenous and intraperitoneal paclitaxel with oral S-1.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Ascitic Fluid; Blood Proteins; | 2015 |
Reduced preoperative serum albumin and absence of peritoneal dissemination may be predictive factors for long-term survival with advanced gastric cancer with positive cytology test.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cis | 2015 |
[S-1 plus Cisplatin Combination Therapy for Gastric Cancer with Peritoneal Dissemination].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Com | 2015 |
[A Case of Long-Term Survival of a Patient with Gastric Cancer with Peritoneal Dissemination].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Gastrectomy | 2015 |
[A Case of Double Cancers of the Stomach and Endometrium with Peritoneal Metastasis].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug C | 2015 |
[A Case of Advanced Gastric Cancer with Peritoneal Dissemination Effectively Treated with S-1 and Docetaxel Combination Chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Doceta | 2015 |
[Introduction of Chemotherapy for Advanced Gastric Cancer Showing Oncologic Emergency Caused by Peritoneal Dissemination--Report of Tow Cases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Ileus; Jaundice, | 2015 |
[A Patient with Gastric Cancer with Peritoneal Dissemination Who Survived for Five Years after Sequential Chemotherapy with S-1 Followed by Paclitaxel].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Combinations; Fat | 2016 |
[Pathological Complete Response to SOX plus Bevacizumab for Treating Stage IV Sigmoid Colon Cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Constipation; Drug Comb | 2016 |
[Outcomes of Staging Laparoscopy in Eight Patients with Positive Peritoneal Washing Cytology after S-1 Administration].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combin | 2016 |
Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2017 |
[A Case of Advanced Gastric Cancer Successfully Treated with Curative Conversion Surgery after Chemotherapy with S-1 plus Oxaliplatin].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Humans; Male; | 2016 |
[A case of gastric cancer with peritoneal dissemination responding to combination chemotherapy with oral fluoropyrimidine and weekly paclitaxel].
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Fema | 2008 |
[A case of Stage IV gastric cancer with liver and peritoneal metastases responding completely to tailored S-1/CPT- 11 combination therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Drug Combinat | 2008 |
[A case of peritoneal disseminated sigmoid colon cancer with liver metastasis responding to S-1].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Combinations; Humans; | 2008 |
Pathological complete response induced by the combination therapy of S-1 and 24-h infusion of cisplatin in two cases initially diagnosed as inoperable advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone | 2008 |
[A case of scirrhous gastric cancer with peritoneal dissemination acquiring stable disease over three years by treatment with oral anticancer drug S-1].
Topics: Adenocarcinoma, Scirrhous; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocol | 2008 |
Pilot study of intraperitoneal administration of paclitaxel and oral S-1 for patients with peritoneal metastasis due to advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Fema | 2008 |
[A case of perforated gastric cancer in which resection for elimination was possible S-1/CDDP combined chemotherapy for peritonitis carcinomatosa].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastroscopy; Hum | 2009 |
[Two advanced gastric cancer cases with peritoneal metastases successfully treated by s-1/paclitaxel combination therapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2009 |
[A resected case of effective treatment with S-1/gemcitabine and Paclitaxel combination chemotherapy for advanced pancreatic cancer with peritoneal and liver metastases].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic C | 2009 |
Octreotide acetate successfully treated a bowel obstruction caused by peritoneally disseminated gastric cancer, thereby enabling the subsequent use of oral S-1 chemotherapy.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined | 2009 |
[A case of gastric cancer with peritoneal dissemination-efficacy of combination therapy with S-1 and docetaxel].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2009 |
Induction chemotherapy with S-1 plus cisplatin followed by surgery for treatment of gastric cancer with peritoneal dissemination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2009 |
[A case of gastric cancer with peritoneal dissemination who achieved long survival by successive treatments with S-1 in combination with CDDP, paclitaxel and irinotecan].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug | 2009 |
[Outcome of therapy for type 4 gastric cancer with peritoneal metastasis--diagnosis by laparoscopy and effect of chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2009 |
[A case of gastric cancer with peritoneal dissemination which has been alive more than three years responding to intraperitoneal chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineopl | 2009 |
[A case of far-advanced gastric cancer with peritoneal dissemination and obstructive jaundice effectively treated with combination chemotherapy and interventional radiology].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2009 |
[A partial response to S-1 as second-line chemotherapy in a patient with unresectable pancreatic cancer].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Combinations; Gemcitabine | 2009 |
[Two cases of advanced gastric cancer with peritoneal dissemination, and Virchow's metastases successfully treated by combination therapy of S-1 and docetaxel].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2010 |
[Combination of S-1 and paclitaxel for advanced/recurrent gastric cancer patients with peritoneal metastasis, feasibility study (OGSG0401)].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2010 |
[A case of type 4 gastric cancer with peritoneal dissemination complicating venous thromboembolism treated effectively by combination of S-1 and warfarin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Combined Modality Therapy; Drug Combinations | 2010 |
Weekly intravenous and intraperitoneal paclitaxel combined with S-1 for malignant ascites due to advanced gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Adm | 2010 |
[Strategy of treatment for gastric cancer with peritoneal metastasis].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Combin | 2010 |
Pilot study of a combination of S-1 and paclitaxel for patients with peritoneal metastasis from gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Hum | 2010 |
[S-1-based chemotherapy for recurrent gastric cancer with peritoneal dissemination resulting in long-term survival--report of a case].
Topics: Antimetabolites, Antineoplastic; Drug Combinations; Fatal Outcome; Humans; Male; Middle Aged; Oxonic | 2010 |
[A very elderly case of recurrent gastric cancer with peritoneal dissemination effectively treated by combination chemotherapy of docetaxel (DOC) and S-1].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Drug Com | 2010 |
[Pharmacokinetic study of S-1 for the treatment of peritoneal metastasis from colon cancer--using a mouse peritoneal metastasis model].
Topics: Administration, Oral; Animals; Cell Line, Tumor; Colonic Neoplasms; Disease Models, Animal; Drug Com | 2010 |
[The effects of gastrojejunostomy for patients with advanced gastric cancer accompanied by peritoneal dissemination].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Combinations; Female; Gastric Bypass; | 2010 |
[An effective treatment by chemotherapy with S-1 and CDDP intraperitoneal administration for the peritoneal dissemination of gastric cancer--a case report].
Topics: Adenocarcinoma; Administration, Oral; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; | 2010 |
[A case of gastric cancer with peritoneal dissemination successfully treated by S-1/paclitaxel combination chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Gastroscopy; Humans; Midd | 2011 |
A case of progressive digital ischemia after early withdrawal of gemcitabine and S-1 in a patient with systemic sclerosis.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2011 |
Good response chemotherapy for late-recurring gastric cancer in the gluteals, with peritoneal and retroperitoneal dissemination.
Topics: Antineoplastic Combined Chemotherapy Protocols; Buttocks; Carcinoma, Signet Ring Cell; Cisplatin; Dr | 2011 |
[A case of gastric carcinoma with peritoneal metastasis successfully treated by combination chemotherapy of S-1 and cisplatin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cisplatin; Combined Modality Therapy; | 2011 |
[Primary adenocarcinoma of small intestine with peritoneal dissemination treated with S-1 and CPT-11 combination chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Ther | 2011 |
[A case of unresectable advanced gastric cancer treated with S-1/low-dose CDDP combination chemotherapy through jejunostomy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Com | 2011 |
Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Ther | 2012 |
Risk factors for peritoneal recurrence in stage II/III gastric cancer patients who received S-1 adjuvant chemotherapy after D2 gastrectomy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Co | 2012 |
[A case report of the combination therapy with S-1 plus CDDP intraperitoneal chemotherapy for CY positive cancer patient].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; | 2011 |
[A case of peritoneal recurrence of invasive carcinoma derived from IPMN after distal pancreatectomy].
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Drug Combinat | 2011 |
[Peritoneal lavage cytology under local anesthesia for detection of peritoneal recurrence after surgery].
Topics: Aged; Anesthesia, Local; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combination | 2011 |
[A case of advanced gastric cancer with peritoneal dissemination successfully treated with S-1 and intraperitoneal docetaxel administration].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Combined Modality Therapy; Docetaxel; | 2012 |
Fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer with peritoneal metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Capecitabine; Cisplatin; Deoxy | 2013 |
[Two cases of advanced gastric cancer with peritonitis carcinomatosa that showed disappearance of ascites and obtained a good quality of life by using DIF and paclitaxel].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Dihydrouracil Dehydrogenase (NADP); D | 2012 |
[A case report of advanced gastric cancer with peritoneal dissemination effectively treated by combination chemotherapy of S-1 and docetaxel].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Humans; Male; Ne | 2012 |
[A case of gastric cancer with peritoneal dissemination who achieved long survival from control of ascites for over 2 years by successive treatments with S-1 in combination with docetaxel as first-line followed by irinotecan in combination with cisplatin
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Camptothecin; Cisplatin; Docetaxel; D | 2012 |
[A long-surviving patient with unresectable advanced gastric cancer treated with S-1 and biweekly paclitaxel combination chemotherapy as second-line treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Fatal Outcome; Humans; Male; Midd | 2012 |
Role of intervention for biliary and gastric/intestinal obstruction in gastric cancer with peritoneal metastasis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholestasis; Drainage; | 2012 |
[A case of gastric cancer with peritoneal dissemination and massive ascites successfully treated with S-1/docetaxel therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Biopsy; Docetaxel; Drug Combinations; Femal | 2012 |
[S-1 monotherapy achieved twenty-month survival for peritoneal lavage cytology-positive gastric cancer patient undergoing noncurative resection].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Ga | 2012 |
[A case of far-advanced gastric cancer successfully treated with S-1/paclitaxel/krestin immunochemotherapy, followed by curative resection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Immunotherapy; Li | 2012 |
[Concentration of FT and CDHP and 5-FU in the ascites fluid of patient with peritoneal carcinomatosis after new anti-cancer drug TS-1 oral administration].
Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Ascitic Fluid; Drug Combinati | 2002 |
[A surgically resected case of advanced gastric carcinoma with peritoneal dissemination after treatment with combined chemotherapy of TS-1 and CDDP].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sched | 2003 |
Prevention of peritoneal metastasis of human gastric cancer cells in nude mice by S-1, a novel oral derivative of 5-Fluorouracil.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Disease Models, Animal; Drug Combina | 2003 |
Chemosensitivity of peritoneal micrometastases as evaluated using a green fluorescence protein (GFP)-tagged human gastric cancer cell line.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Ascites; Carcinoma; Cell Count; Dose | 2003 |
Experimental study to evaluate the usefulness of S-1 in a model of peritoneal dissemination of gastric cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Disease Models, Animal; Drug Combinations; Ea | 2003 |
Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: results from a post-marketing survey.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Drug Evaluation; Fe | 2003 |
Longterm control of advanced and recurrent gastric cancer (ARGC) by S-1.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; D | 2003 |
Dihydropyrimidine dehydrogenase (DPD) activity in gastric cancer tissue and effect of DPD inhibitory fluoropyrimidines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehyd | 2003 |
[A case of peritoneal metastasis of gastric cancer responding to TS-1, administered for four consecutive weeks with two-week rests].
Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Drug Combinations; Humans; Ma | 2003 |
[A case of advanced type 4 gastric cancer with peritonitis dissemination, navel metastasis effectively treated with combined chemotherapy of biweekly paclitaxel (TXL) and TS-1].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colectomy; Colonic Di | 2003 |
[Efficacy of TS-1 in patients with peritonitis carcinomatosa from gastric cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Administration Schedul | 2003 |
[A case of gastric cancer with peritoneal dissemination which showed the intraperitoneal CR by administrating TS-1 orally and paclitaxel intraperitoneally].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sche | 2003 |
[Two resected cases of advanced gastric cancer with peritoneal dissemination after successful treatment with TS-1 plus low-dose CDDP].
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationshi | 2003 |
[A case of type 4 gastric cancer with peritoneal dissemination successfully treated over 2 years by alternate-day administration of TS-1].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Carcinoma, Signet Ring Cell; Drug Administration Sc | 2004 |
[A case of gastric cancer with umbilical metastasis that responded to TS-1 with low-dose cis-platinum].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Cisplat | 2004 |
[A case of advanced colon cancer with peritoneal dissemination completely responding to TS-1].
Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Colectomy; Colonic Neoplasms; | 2004 |
[TS-1 was prescribed for a patient with stomach cancer with peritoneal dissemination who survived for 3 years and 2 months].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Administration | 2004 |
Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 may be effective against peritoneal dissemination in gastric cancer.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Ascites; Dihydrouracil Dehydrogenase | 2004 |
[A case of recurrent gastric cancer with peritoneal dissemination successfully treated with DJ stents against bilateral hydronephrosis and chemotherapy].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Combined M | 2004 |
[A case of a nonresected gastric cancer with peritoneal dissemination maintained on TS-1 and docetaxel combination chemotherapy with good QOL].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration | 2005 |
[A case of advanced gastric cancer with peritoneal dissemination effectively treated by combined chemotherapy of paclitaxel (TXL) and TS-1].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Drug Administration Sch | 2005 |
[TS-1 treatment for progressive gastric cancer in a patient on chronic dialysis--assessment of dosage regimen by monitoring blood concentrations of therapeutic drugs (TDM)].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Area Under Curve; Drug Administration Schedu | 2005 |
[TS-1 therapy via intestinal catheter used for tube feeding in a patient with gastric cancer after total gastrectomy].
Topics: Aged; Antimetabolites, Antineoplastic; Catheterization; Combined Modality Therapy; Drug Administrati | 2005 |
[A case of remnant gastric cancer with multiple bone metastasis and peritoneal dissemination; efficacy of combination therapy of docetaxel and TS-1].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modal | 2005 |
[A case of gastric cancer with peritoneal recurrence which developed during adjuvant administration of TS-1 showing complete response by weekly docetaxel regimen].
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; | 2005 |
[Preoperative combination chemotherapy with TS-1 is effective in a case gastric cancer with peritoneal dissemination].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Ascites; Cisplatin; Drug Administrat | 2005 |
[Peritoneal dissemination of scirrhous type 4 gastric cancers].
Topics: Adenocarcinoma, Scirrhous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; C | 2005 |
[Treatment strategy for primary gastric cancer with peritoneal dissemination].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Flu | 2005 |
[Prediction and treatment of peritoneal dissemination in gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combination | 2005 |
[Two cases of advanced gastric cancer, successfully treated with TS-1/CDDP combination chemotherapy--case report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sched | 2005 |
[Effect of intraperitoneal chemotherapy on experimental peritoneal dissemination of gastric cancer].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carboplatin; Cisplatin; Docetaxel; | 2005 |
[Safety and efficacy of chemotherapy using TS-1 followed by paclitaxel for advanced or recurrent gastric cancer with peritoneal dissemination].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; | 2005 |
[A case of peritoneal dissemination disappeared by CPT-11 + TS-1 combination chemotherapy].
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Ant | 2005 |
[Two cases of advanced gastric cancer with peritoneal dissemination acquired long-term response three years or more by postoperative treatment with oral anticancer drug TS-1].
Topics: Adenocarcinoma, Mucinous; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Combined Moda | 2006 |
[Liver metastasis from sigmoid colon cancer with peritoneal dissemination showed a complete response to TS-1].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoembryoni | 2006 |
A synergic inhibitory-effect of combination with selective cyclooxygenase-2 inhibitor and S-1 on the peritoneal metastasis for scirrhous gastric cancer cells.
Topics: Adenocarcinoma, Scirrhous; Animals; Antimetabolites, Antineoplastic; Benzenesulfonates; Cyclooxygena | 2006 |
[A case of gastric cancer with peritoneal dissemination who achieved five-year survival by successive treatments with TS-1 alone and in combination with other drugs].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; | 2006 |
[Two cases of gastric cancer with peritoneal dissemination that responded to TS-1 without progression or recurrence for over 3 years].
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Administration Schedule; Drug | 2006 |
[A case of nonresected gastric cancer with peritoneal dissemination maintained on TS-1, cisplatin (CDDP) and docetaxel combination chemotherapy with good QOL].
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Cardia; Cisplatin; Docetax | 2006 |
[A case of recurrent gastric cancer with peritoneal dissemination successfully treated over 1 year 8 months with combined chemotherapy of paclitaxel and TS-1].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Admi | 2006 |
[Successful bi-weekly paclitaxel treatment of an AFP-producing gastric cancer patient with peritoneal dissemination and multiple liver metastasis].
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Drug Adminis | 2006 |
Pharmacokinetics of S-1 in patients with peritoneal dissemination of gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biological Availability; Drug Combinations; Female; Fl | 2006 |
[A case of long-term survival of gastric cancer with peritoneal metastasis effectively treated by TS-1 and paclitaxel (PTX) combination therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Constriction, Pathologic; Drug Administra | 2006 |
Efficacy of S-1 for patients with peritoneal metastasis of gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Dihydrouracil Dehydrogenase (NADP); | 2006 |
[A case of duodenal carcinoma with massive peritoneal carcinomatosis complicating a pulmonary embolism].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Drug T | 2006 |
[A case of advanced gastric cancer with peritoneal dissemination responding remarkably to TS-1/CDDP combination chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sched | 2006 |
[A case of paclitaxel-resistant cancerous ascites secondary to gastric carcinoma responding well to TS-1 therapy].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Ascites; Drug Administration Schedule; Drug Comb | 2006 |
[Two cases of primary peritoneal cystadenocarcinoma--diagnosis, treatment, and clinical feature].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystadenocarcino | 2006 |
[A case report of advanced gastric cancer with carcinomatous ascites successfully treated by outpatient chemotherapy].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Ascites; Ascitic Fluid; Cisplatin; | 2007 |
[A case of advanced gastric cancer with peritoneal dissemination effectively treated with fourth-line chemotherapy of S-1 alone].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinati | 2007 |
[Case of advanced gastric cancer successfully treated with chemotherapy of weekly paclitaxel].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Cisplatin; Drug Administration Schedule; Dr | 2007 |
Long-term outcomes of patients with metastatic gastric cancer after initial S-1 monotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Disease Progression; Disease-Free Survival; Drug Combi | 2007 |
[Prolonged complete response obtained by single agent S-1 in a case of peritoneal metastasis from gastric remnant cancer].
Topics: Antimetabolites, Antineoplastic; Drug Combinations; Gastric Stump; Humans; Male; Middle Aged; Neopla | 2007 |
[Retrospective analysis of treatment for advanced gastric cancer with peritoneal dissemination].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 2007 |
[A case of advanced gastric cancer with peritoneal dissemination responding to S-1/CDDP neoadjuvant chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sched | 2007 |
Intraperitoneal administration of paclitaxel and oral S-1 for a patient with peritoneal dissemination and hydronephrosis due to advanced gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Antineoplastic Agents; Antineoplastic Combined Chemothe | 2007 |
[A case report of curative resection for gastric cancer with peritoneal dissemination successfully treated by combined chemotherapy of S-1 and paclitaxel].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic C | 2008 |
[A case of advanced gastric cancer with peritoneal metastasis successfully treated over 19 months with postoperative chemotherapy after non-curative surgery].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2008 |
[A case of advanced gastric cancer with Schnitzler's metastases effectively treated by the combination of paclitaxel and S-1].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2008 |
Complete response of highly advanced gastric cancer with peritoneal dissemination after new combined chemotherapy of S-1 and low-dose cisplatin: report of a case.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cis | 2001 |
Unusual survival for more than 2 years with peritoneal metastases of gastric cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Gastrectomy; | 2002 |
[Three cases of recurrent gastric cancer responding to TS-1 therapy following combination therapy with 5-fluorouracil, mitomycin C and cisplatin].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administ | 2002 |
[Evaluation of the efficacy of TS-1 for peritoneal dissemination of gastric cancer using a newly-developed animal model].
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Disease Models, Animal; Drug Combina | 2002 |